



Review

Cannabidiol and the Canonical WNT/ β -Catenin Pathway in Glaucoma

Alexandre Vallée ^{1,*} , Yves Lecarpentier ² and Jean-Noël Vallée ^{3,4}

¹ Department of Clinical Research and Innovation (DRCI), Foch Hospital, 92150 Suresnes, France

² Centre de Recherche Clinique, Grand Hôpital de l'Est Francilien (GHEF), 6-8 rue Saint-Fiacre, 77100 Meaux, France; yves.c.lecarpentier@gmail.com

³ Centre Hospitalier Universitaire (CHU) Amiens Picardie, Université Picardie Jules Verne (UPJV), 80054 Amiens, France; valleejn@gmail.com

⁴ Laboratoire de Mathématiques et Applications (LMA), UMR CNRS 7348, Université de Poitiers, 86000 Poitiers, France

* Correspondence: alexandre.g.vallee@gmail.com

Abstract: Glaucoma is a progressive neurodegenerative disease which constitutes the main frequent cause of irreversible blindness. Recent findings have shown that oxidative stress, inflammation and glutamatergic pathway play key roles in the causes of glaucoma. Recent studies have shown a down regulation of the WNT/ β -catenin pathway in glaucoma, associated with overactivation of the GSK-3 β signaling. WNT/ β -catenin pathway is mainly associated with oxidative stress, inflammation and glutamatergic pathway. Cannabidiol (CBD) is a non-psychotomimetic phytocannabinoid derived from Cannabis sativa plant which possesses many therapeutic properties across a range of neuropsychiatric disorders. Since few years, CBD presents an increased interest as a possible drug in anxiolytic disorders. CBD administration is associated with increase of the WNT/ β -catenin pathway and decrease of the GSK-3 β activity. CBD has a lower affinity for CB1 but can act through other signaling in glaucoma, including the WNT/ β -catenin pathway. CBD downregulates GSK3- β activity, an inhibitor of WNT/ β -catenin pathway. Moreover, CBD was reported to suppress pro-inflammatory signaling and neuroinflammation, oxidative stress and glutamatergic pathway. Thus, this review focuses on the potential effects of cannabidiol, as a potential therapeutic strategy, on glaucoma and some of the presumed mechanisms by which this phytocannabinoid provides its possible benefit properties through the WNT/ β -catenin pathway.



Citation: Vallée, A.; Lecarpentier, Y.; Vallée, J.-N. Cannabidiol and the Canonical WNT/ β -Catenin Pathway in Glaucoma. *Int. J. Mol. Sci.* **2021**, *22*, 3798. <https://doi.org/10.3390/ijms22073798>

Academic Editor: Stephanie C. Joachim

Received: 8 February 2021

Accepted: 22 March 2021

Published: 6 April 2021

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

Keywords: WNT/ β -catenin pathway; cannabidiol; inflammation; oxidative stress; glutamatergic pathway; glaucoma

1. Introduction

Glaucoma is a progressive neurodegenerative disease that constitutes the main frequent cause of irreversible blindness. The number of people with glaucoma worldwide will increase from 76.5 million in 2020 to 111.8 million by 2040, mainly due to the aging of the population [1–3]. Glaucoma is characterized by loss of retinal ganglion cells (RGCs), thinning of the retinal nerve fiber layer, and cupping of the optic disc [4]. Glaucoma is a group of heterogeneous diseases characterized by varying clinical features. Aging, increased intraocular pressure (IOP), and genetic background are the main risk factors for glaucoma [4]. Primary open-angle glaucoma (POAG) is the main form in Western countries. Nevertheless, 30% of Caucasian patients with POAG, and a greater proportion of the Asian population show normal-tension glaucoma (NTG) [5]. The etiology of POAG is mainly described as mechanical and/or vascular processes. The mechanical process enhances compression of the axons due to elevation of IOP, whereas the vascular process highlights events in which blood flow and ocular perfusion pressure are diminished in the posterior pole [6,7]. Vascular or perfusion dysregulations in NTG present different clinical features,

such as migraine headaches, Raynaud's phenomenon or sleep apnea [8]. In high IOP glaucoma, both the anterior and posterior segments are damaged, and extensive affection is detectable in the trabecular meshwork (TM) and along the inner retina-central visual pathway [9].

Pathogenic processes of the neurodegenerative mechanism lead to mechanical and vascular stress enhancing mitochondrial dysregulation, chronic oxidative stress (OS) and metabolic stress [10,11], excitotoxicity [12], and neuroinflammation [13,14]. OS and cell senescence are increased in the aging retina [15,16] and are considered as the major glaucoma risk factors. In the aging retina, OS leads to the activation of a local para-inflammation of various magnitudes [17]. Para-inflammation, in glaucoma, is characterized by a tissue adaptive response to noxious stress [17]. However, a physiological stage of para-inflammation is needed to maintain homeostasis but when tissue is exposed to chronic stress, inflammation may have a negative role and could be involved in both initiation and progression of the disease [18]. The deregulation of para-inflammation, in the retina, is a response to stress stimuli, especially chronic OS. However, excessive and uncontrolled para-inflammation could implicate inflammatory responses with a release of cytokines/chemokines leading to neuroretina damages [19]. Para-inflammatory dysregulation could be associated with TM dysfunction and increased resistance to aqueous outflow, the main cause of increased IOP in POAG [9].

The trabecular meshwork was the main pathological localization of PAOG [20]. A balance between the production and outflow of the aqueous humor can control IOP. The TM is formed by layers of trabecular beams, and is surrounded by elastic fibers, fibronectin and laminin. Abnormalities of the extracellular matrix (ECM) are involved in high IOP [21]. Recently, the WNT/ β -catenin pathway has been found to be associated with the development of glaucoma in the TM [22].

Since the early 1970s, cannabinoids (CBs) have been investigated as anti-glaucoma drugs [23]. Cannabinoids are a large class of chemical components from the trichomes and the leaves of *Cannabis* plants (phytocannabinoids) or produced by pharmacological synthesis (synthetic cannabinoids). These molecules interact with cannabinoid receptor 1 (CB1) and cannabinoid receptor 2 (CB2) which are the natural receptors of endocannabinoids modulating numerous physiological mechanisms [24]. CB1 and CB2 are expressed in human retina, ciliary body and retinal pigment epithelium, administration of exogenous cannabinoids could act on numerous retinal mechanisms including signal transduction, photo-transduction and IOP control [25,26]. CBs have been widely investigated as IOP lowering treatments [27] and possess many benefits in glaucoma [25,27,28]. Besides IOP lowering capabilities, CBs present major neuroprotective actions on the nervous system [28,29]. CBs can inhibit glutamate release and diminish oxidative stress [27].

Cannabidiol (CBD) is a non-psychotomimetic phytocannabinoid derived from *Cannabis sativa* plant which possesses many therapeutic properties across a range of neuropsychiatric disorders [30,31]. For a few years, CBD has presented increased interest as potential anxiolytic therapy [32–34]. CBD has a lower affinity for CB1 but can act through other signaling ways in glaucoma. CBD downregulates GSK3- β activity, an inhibitor of WNT/ β -catenin pathway [35]. Moreover, CBD has been reported to suppress pro-inflammatory signaling and neuroinflammation [36,37], oxidative stress [38] and glutamatergic pathway [39].

Thus, this review focuses on the potential effects of cannabidiol, as a potential therapeutic strategy, on glaucoma and some of the presumed mechanisms by which this phytocannabinoid provides its possible benefit properties through the WNT/ β -catenin pathway.

2. Pathophysiology of Glaucoma

In PAOG, the IOP increase leads to the TM occlusion induced by the iris tissue [9]. Chronic contact between the iris and the TM can lead to permanent damage to the TM. The TM dysfunction and the reduction of its cellularity are the first steps to the high tension glaucoma (HTG) onset, including POAG and also PACG (primary angle-closure glaucoma). Numerous factors, including OS and aging, as well as environmental factors

are implicated as the promoters of TM damage [40]. OS could be enhanced in the morphological alterations of the TM of glaucomatous eyes, due to it stimulating inflammatory response. Chronic inflammation and OS modulate each other in a vicious circle influencing cellular responses. Cultures of TM present an NF- κ B pathway activation after exogenous stimulation including IL1 or H₂O₂. The NF- κ B activation results in a significant expression of the endothelial leukocyte adhesion molecule-1 (ELAM-1), IL-1 β and IL-6 [41]. ELAM-1 belongs to selectin families, which are cell adhesion molecules. The presence of ELAM-1 in POAG is considered to be a factor in the onset of TM endothelial dysfunction [42].

During glaucoma, a progressive loss of TM cells has been shown, due to the combination of both aging and stress conditions [43]. In HTG, the TM displays both chronic inflammation and tissue reprogramming mechanisms associated with OS damage and endothelial dysfunction [44]. Among the pro-inflammatory cytokines, IL6, IL1 and TNF-alpha can induce ECM remodeling and alter cytoskeletal interactions in the glaucomatous TM [42]. The alterations in the protein patterns observed in the aqueous humor (AH) of POAG patients are the consequence of the progressive loss of TM cellular integrity [45]. The TM is the most sensitive tissue of the anterior segment of the eye to oxidative stress [46]. Glaucomatous TM cells present POAG-typical molecular modifications, such as ECM accumulation, cell death, dysregulation of the cytoskeleton, advanced senescence, NF- κ B stimulation and the release of inflammatory markers [41,47].

These findings may suggest that the IOP elevation, which occurs in glaucoma, is associated with oxidative degenerative processes damaging the human TM endothelial cells (hTMEs). Chronic exposure of TM cells to OS leads to numerous changes in the lysosomal pathway responsible for autophagia [48], as well as cell senescence with an increase in senescence-associated-galactosidase [49]. OS induces a lysosomal dysregulation and the defective proteolytic stimulation of lysosomal enzymes with a subsequent decrease in autophagic flux and the promotion of cell senescence [9].

The IOP elevation, either at the lamina cribrosa or the optic nerve head (ONH) level, leads to hypoperfusion and to reperfusion damages [50]. IOP elevation is considered as a cause of retinal ganglion cells (RGCs) damage, resulting in a retrograde transport blockade and the accumulation of neurotrophic factors at the lamina cribrosa instead of reaching the RGC soma [51]. The POAG etiology is still unclear but several risk factors have been observed as the causes of promoting its onset, such as elevated IOP, aging, gender, ethnicity, first-degree family history of glaucoma, oxidative stress, systemic and ocular vascular factors, and inflammation [52].

3. Oxidative Stress, Inflammation and Glutamate in Glaucoma

The mechanisms of ROS production are activated in several pathological conditions of the retina, such as glaucoma, occlusion of the central artery of the retina and age-related macular degeneration. They are enzymes, including the nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, the xanthine oxidoreductase, the cytochrome P450, the mitochondrial cytochrome oxidase and the eNOS decoupled, which catalyzes the overproduction of ROS in the tissues of the vascular system [53,54]. Oxidation decreases tetrahydrobiopterin (BH4) bioavailability, whereas it increases the 7,8-dihydrobiopterin (BH2) competing with BH4 to enhance eNOS [55].

To date, the visual loss processes are not entirely elucidated in glaucoma, and ROS production plays an important role in its development [56]. ROS production rates are increased in patients with glaucoma in the aqueous humor but also in the blood serum [57]. One of the main factors for glaucoma risk is elevated IOP. A moderately elevated IOP increases ROS production levels, stimulates NOX2 expression, and endothelial dysregulation in retinal arteries, suggesting that IOP augmentation affects the vascular function of the retina [58]. However, there are other pathogenic processes linked to glaucoma, including glutamate excitotoxicity [59], which are not necessarily associated with the elevated levels of IOP [56]. It seems that the death of RGCs during a glaucoma process stimulates ROS production in vitro [60]. It has been shown that ROS production controls the immune

response by stimulating the action of antigen glial cells [60]. The ROS production affects the retina, and increases IOP to induce dysfunction of the support glia, which facilitates the secondary degeneration of the RGCs in glaucoma [61].

The immune system is regulated by several inflammatory factors, such as tumor necrosis factor α (TNF- α), interleukin-6 (IL-6), vascular endothelial growth factor (VEGF) and tumor growth factor- β (TGF- β) [62]. Chronic inflammation is also responsible for the increase of cyclooxygenase 2 (COX-2, a prostaglandin-endoperoxidase synthase) [63]. Numerous cytokines (TNF- α , IL-1) activate COX-2 [64]. COX-2 stimulates ROS and RNS production [63,65]. Nuclear factor- κ B (NF- κ B) stimulates several pro-inflammatory factors that activate COX-2 and inducible nitric oxide synthase (iNOS) [66]. Several studies have shown that NF- κ B stimulates the expression of TNF- α , IL-6, IL-8, STAT3, COX-2, B-cell lymphoma 2 (BCL-2), metalloproteinases (MMPs), VEGF [66], and the ROS production [67]. Furthermore, iNOS, an enzyme catalyzing nitric oxide (NO), is activated during chronic inflammation [68].

Several pieces of research have shown the mechanism by which oxidative stress can lead to chronic inflammation [69]. The imbalance caused by oxidative stress leads to damage signaling in cells [70]. The ROS production plays a central role both upstream and downstream of NF- κ B and TNF- α pathways, which are the main mediators of the inflammatory response. The hydroxyl radical is the most harmful of all the ROS. A vicious loop is observed between ROS and these pathways. ROSs are generated by NADPH oxidase (NOX) system. Moreover, the modified proteins by ROS could generate an initiation of auto-immune response to stimulate TNF- α and NOX [71]. Nuclear factor erythroid-2 related factor 2 (Nrf2) is mainly associated with oxidative stress in inflammation [69]. Nrf2 is a transcription factor that binds to the antioxidant response element (ARE) [72]. Several studies have shown that Nrf2 can present an anti-inflammatory role by regulating MAPK, NF- κ B, and PI3K pathways [73]. Thus, Nrf2 may play a major role against oxidative damages [74]. Furthermore, evidence also suggests that mitochondrial dysregulation has a significant role in the cancer mechanism [69].

Glutamate is an amino-acid responsible for the brain's primary excitatory neurotransmission [75]. Glutamatergic neurons are embedded in every brain circuit in comparison to dopamine and serotonin which are used by a small minority of neural cells in the brain. Glutamate is the main excitatory neurotransmitter in the brain and is present in more than 50% of synapses. This signaling plays a major role in neuronal plasticity, memory and learning [76]. Rapid neurotoxicity enhanced by neuronal excitotoxin has been observed with abnormal glutamate levels [77]. In neurons, glutamate is stored in synaptic vesicles from which it is released. Glutamate release increases glutamate concentration in the synaptic cleft to bind ionotropic glutamate receptors. The main consistent candidate gene in OCD is SLC1A1 (solute carrier, family 1, member 1) gene [78]. SLC1A1 encodes for the neuronal excitatory Na⁺-dependent amino acid transporter 3 (EAAT3). EAAT1 and EAAT2 are the main astrocyte glutamate transporters whereas EAAT3 is the major neuronal glutamate transporter. Glutamate is converted into glutamine in astrocytes. Then, glutamine is captured by the presynaptic neurons to be re-converted into glutamate [79]. The role of the EAAT3 is to control glutamate spillover (signification de spillover?) which affects pre-synaptic N-methyl-D-aspartate (NMDA) and metabotropic glutamate receptors activity [80,81]. EAAT3 activity is dysregulated by the overexpression of GSK-3 β [82].

In glaucoma, the glutamate toxicity could contribute to RGC death and appears to be mediated mainly by the NMDA receptor that, apart from promoting cell death, due to its greater Ca²⁺ permeability, has a high affinity for glutamate and a slow inactivation [83,84]. Glutamate excitotoxicity is implicated in the mtDNA alteration or DNAoxidation-related mitochondrial dysregulation in retinal neurodegeneration [85]. Glutamate excitotoxicity over-activity leads to neuronal cell death through high levels of glutamate and the over-activation of NMDA receptors. The excitotoxic affection to RGCs may be involved by the increased glutamate synthesis or a decreased glutamate clearance [86].

4. WNT/ β -Catenin Pathway

WNT name is derived from Wingless drosophila melanogaster and its mouse homolog Int. WNT/ β -catenin pathway is involved in numerous signaling and regulating pathways, such as embryogenesis, cell proliferation, migration and polarity, apoptosis, and organogenesis [87]. However, during numerous pathological states, the WNT/ β -catenin pathway can be dysregulated, such as inflammatory, metabolic and neurological disorders, tissue fibrosis and cancers [88].

The WNT pathway belongs to the family of secreted lipid-modified glycoproteins [89]. WNT ligands are secreted by both neurons and immune cells located in the central nervous system [90]. WNT pathway dysregulation contributes to several neurodegenerative diseases [91–95]. The WNT pathway has the main step known as the β -catenin/T-cell factor/lymphoid enhancer factor (TCF/LEF). Cytosolic accumulation of β -catenin is controlled by the destruction complex AXIN, tumor suppressor adenomatous polyposis coli (APC), and glycogen synthase kinase-3 (GSK-3 β). Without WNT ligands, the destruction complex participates in hyper-phosphorylate cytoplasmic β -catenin and leads to its proteasomal degradation. However, in their presence, the WNT ligands bind to Frizzled (FZL) and LDL receptor-related protein 5/6 (LRP 5/6) interrupting the destruction complex and preventing β -catenin degradation into the proteasome. β -catenin translocates to the nucleus where it interacts with TCF/LEF. This activates WNT target genes [96–98].

Glycogen synthase kinase-3 β (GSK-3 β) is one of the main inhibitors of the WNT/ β -catenin pathway [99–104]. As an intracellular serine-threonine kinase, GSK-3 β is a key negative regulator of the WNT pathway [105]. It is involved in the regulation of several kinds of pathophysiological signaling, such as cell membrane signaling, cell polarity, and inflammation [106–108]. GSK-3 β acts by inhibiting cytoplasmic β -catenin and stabilizes it to induce its nuclear migration. Inflammation is an age-related process associated with the increase of GSK-3 β activity and the decrease of the WNT/ β -catenin pathways [109].

Recent studies have observed that glaucoma patients present an increased GSK-3 β activity and thus its inhibition could be an interesting treatment [110,111]. GSK-3 β is a serine/threonine kinase that is involved in numerous intracellular signaling pathways. Dysfunction of GSK-3 β is involved in the pathogenesis of several diseases, including neuropsychiatric disorders [112]. GSK3 β is known to be the major inhibitor of the canonical WNT/ β -catenin pathway [103,113–117].

5. WNT/ β -Catenin Pathway in Glaucoma

Recent studies have shown that the WNT/ β -catenin pathway is involved in the pathophysiology of TM cells. This pathway could serve as a regulator of IOP [118]. Secreted frizzled-related protein 1 (sFRP1), a WNT inhibitor, is elevated in the glaucomatous TM. Exogenous sFRP1 involves high IOP [119,120]. In sFRP1-perfused human eyes, the level of β -catenin is decreased [119]. sFRP1 is associated with cell stiffness [120]. TM cells have multiple responses to the stimulus by different concentrations of sFRP1 [120]. It has been illustrated that sFRP1 is elevated in normal TM cells grown on substrates simulating the stiffness of the glaucomatous TM. Increased stiffness of the TM involves the aqueous humor outflow resistance and is leading to elevated IOP [120]. Moreover, the GSK3 β , another WNT inhibitor, can decrease the activity of the WNT/ β -catenin pathway and lead to ocular hypertension in association with sFRP1 [119]. It has been shown that there are two effects of WNT in glaucoma [118]. The glaucoma gene myocilin (MYOC) has been shown to be a regulator of WNT/ β -catenin pathway [121]. Nevertheless, the damages induced by MYOC mutation on the WNT pathway remain unclear in the TM. The aqueous humor outflow resistance is damaged by the change in adhesion junctions and cell contact, and then IOP is dysregulated [118]. The WNT/ β -catenin pathway is believed to be a novel interventional target for the treatment of glaucoma [122–124]. Several WNT target genes are expressed in the TM, and the WNT ligand WNT3a is dysregulated [118,119]. The overexpression of both sFRP1 or Dkk1 can increase IOP in perfusion-cultured human eyes and in mouse eyes [118,119]. Moreover, the cotreatment with a small-molecule WNT pathway activator

can downregulate sFRP1-induced OHT in mouse eyes. The activation of WNT/ β -catenin pathway in the TM using lithium chloride decreases the production of some ECM and matricellular proteins [125,126]. WNT/ β -catenin signaling and K-cadherin expression are major for the control of IOP, and the downregulation of this pathway leads to IOP elevation in glaucoma [127]. Recent studies have shown that active WNT/ β -catenin pathway inhibits fibrosis-associated proteins in the TM and that the POAG-associated WNT antagonist sFRP1 increases ECM deposition, TM cell stiffness [120] and IOP [118,119]. Moreover, recent findings have shown that the WNT/ β -catenin can regulate TM homeostasis and IOP by a cross-inhibit circle with TGF- β signaling [126].

6. WNT/ β -Catenin Pathway and the Altered Pathways in Glaucoma

6.1. WNT/ β -Catenin Pathway and Oxidative Stress

FoxO (Forkhead box class O) transcription factors are the main intracellular controllers of numerous metabolic signaling such as glucose production, and the cellular response to oxidative stress [128]. ROS production is associated with the inhibition of the WNT pathway by diverting β -catenin from TCF/LEF to FoxO [129]. This leads to the accumulation and binding of β -catenin to FoxO as a cofactor, and in increasing FoxO transcriptional activity in the nucleus [130,131]. FoxO stimulates apoptotic genes [132–134]. FoxO3a stops the cell-cycle by stimulation of the production of the cyclin-dependent kinase inhibitor p27 kip1 and the inhibition of cyclin D1 expression [135,136]. The activation of FoxO induces apoptosis [137]. However, the activation of the WNT pathway can downregulate FoxO3a in the cytosol to prevent the loss of mitochondrial membrane permeability, cytochrome c release, Bad phosphorylation, and activation of caspases which activates ROS production and oxidative stress [138].

6.2. WNT/ β -Catenin Pathway and Inflammation

The stimulation of the WNT pathway cascade restrains inflammation and leads to neuroprotection via interactions between microglia/macrophages and astrocytes [139,140].

Several studies have shown negative crosstalk between WNT/ β -catenin pathway and NF- κ B pathway, one of the main markers of inflammation [141]. The NF- κ B transcription factor family belongs to five members in the cytosol under non-activated conditions: NF- κ B 1 (p50/p105), NF- κ B 2 (p52/p100), RelA (p65), RelB and c-Rel [142]. β -catenin complexes with RelA and p50 to diminish the activity of the NF- κ B signaling [143]. Moreover, by interacting with the PI3K, β -catenin inhibits the functional activity of NF- κ B [144]. This inhibitory function of β -catenin on NF- κ B activity has been observed in numerous cell types, such as fibroblasts, epithelial cells, hepatocytes and osteoblasts [141]. In parallel, the overactivation of GSK-3 β leads to an inhibition of the β -catenin and then an activation of the NF- κ B pathway [145]. The potential protective action of β -catenin was due to the activation of PI3K/Akt pathway and thus the reduction of TLR4-driven inflammatory response in hepatocytes [146]. NF- κ B activation leads to the diminution of the complex β -catenin/TCF/LEF by the upregulation of LZTS2 in cancer cells [147]. DKK, a WNT inhibitor, was a target gene of the NF- κ B pathway leading to negative feedback to diminish the β -catenin signaling [148]. Activated β -catenin inhibits the NF- κ B-mediated transcription of pro-inflammatory genes. This effect is controlled by the GSK-3 β . GSK-3 β is a direct inhibitor of the β -catenin levels and an activator of the NF- κ B pathway [149,150].

6.3. WNT/ β -Catenin Pathway and Glutamatergic Pathway

β -catenin activates EAAT2 and glutamine synthetase (GS) at the transcriptional level in progenitor-derived astrocytes through the activation of TCF/LEF [151]. The knockdown of β -catenin leads to the diminution of EAAT2 and GS expression in the prefrontal cortex [152]. In astrocytes, the inhibition of β -catenin is associated with diminution of both EAAT2 and GS expression [153]. The dysregulation of the WNT/ β -catenin pathway induces glutamate excitotoxicity resulting in the increase of both inflammation and exudative stress [153].

7. Cannabidiol

Cannabinoids refer to a heterogeneous group of compounds classified into three major groups: endogenous, synthetic and phytocannabinoids [31,154]. CBD is a non-psychotomimetic phytocannabinoid derived from *Cannabis sativa* plant. The *Cannabis sativa* plant produces more than 66 compounds, such as delta9-tetrahydrocannabinol (THC), responsible for anxiogenic effects, and CBD, the major non-psychotomimetic compound in the plant [155]. CBD attenuates brain damage associated with neurodegeneration. Humans tolerate a high dose of CBD [156]. Moreover, CBD can interact with synaptic plasticity and induces neurogenesis. The mechanisms of the CBD effects remain unclear but have multiple pharmacological targets. Traditional medicines use *Cannabis sativa* for centuries. CBD, one of the main compounds of *Cannabis sativa*, has recently presented numerous interesting actions in many neuropsychiatric disorders [157]. CBD presents a large spectrum of possible therapeutic properties such as anxiolytic, antidepressant, neuroprotective, anti-inflammatory and immunomodulatory [31]. Cannabinoids could be considered as a new class of drugs because of their possible actions on neuropsychiatric disorders [158]. CBD has a potential therapeutic role in neuropsychiatric disorders such as schizophrenia, epilepsy, addiction and neonatal hypoxic-ischemic encephalopathy [159]. CBD can activate WNT/ β -catenin and PI3K/Akt pathways and produces therapeutic effects in schizophrenia [160–162].

8. Cannabinoids in Glaucoma

CBs could have a major role in IOP control through the interaction with the ciliary muscle and Schlemm's canal, and by the modulation of cyclooxygenase-2 (COX-2) [163]. These actions are obtained by the interaction with CB1 receptor but also by the modulation of cyclooxygenase (COX) pathway [164]. CB1 is expressed in both retina and anterior eye structures including TM, Schlemm's canal, iris, ciliary body muscle, and ciliary pigmented epithelium. Several pathways could be implicated in the IOP lowering action of CBs by the regulation of aqueous humor production and outflow (trabecular and uveoscleral) [165]. Activation of the CB1 receptor in the ciliary muscle could also induce vasodilatation with consequent reduction of aqueous humor production [166]. Nevertheless, the exact role of CBs in the regulation of IOP remains unclear [27]. In parallel, CBs inhibit glutamate and nitric oxide release by the activation of pre-synaptic CB receptors leading to higher neuronal excitability and synaptic plasticity [28]. Glutamate pathway can regulate the RGC death through the stimulation of nitric oxide synthase and the increase in oxidative damages. Glutamate pathway in glaucoma is well investigated [27]. The anti-inflammatory actions of CBs could also have a role in neuroprotection. Stimulation of CB1 and CB2 receptors in the retina and CNS downregulates the production of nitric oxide and inflammatory cytokines which are responsible for OS and RGC death [167]. In the TM, the reduction of OS could also be obtained by ROS blockage without any CB receptor activation, such as activation of the WNT pathway [168].

Nevertheless, CBD could have an opposing effect on IOP by increasing or decreasing it [169]. The increase of IOP by CBD could be the result of the antagonist role of CBD on CB1 receptor [169]. The absence of the effect of CBD on IOP could be due to the direct and indirect activity at GPR18 receptor and CB1 receptor which could be both deleted. CBD is activated on GPR18 [170] to interrupt the activity of FAAH [171], responsible for the elevation of acylethanol-amines, such as AEA, one of the precursor of GPR18 [172]. Diurnal action of CB1 and activation of GPR18 remain unstudied. Time of day and broadly speaking pressure, which is higher during the day, regulate the pressure in the eye. Mice present a nocturnal and reversed cycle of GPR18 which participate in lowering eye pressure. Thus, diurnal signaling should have a major role in the ocular response of CBD, which is different between humans and mice [173]. Moreover, gender different effects could be involved in IOP-response to CBD, by interacting with GPR119 ligand. Female mice show lower ocular pressure under CBD administration, whereas it is not the case for male mice [174].

Furthermore, a low dose of CBD administration may have no significant IOP-lowering effect [27,175]. However, these different mechanisms remain unclear.

9. Activation of the Canonical WNT Pathway by Cannabidiol: A Potential Therapeutic Strategy for the Altered Pathways in Glaucoma

9.1. Cannabidiol and WNT Pathway

Dysfunction of GSK-3 β is involved in the pathogenesis of several diseases, including neuropsychiatric disorders [112]. GSK-3 β is a regulator of several pathways such as inflammation, neuronal polarity or either cell membrane signaling [107]. GSK3 β is known to be the main inhibitor of the WNT/ β -catenin signaling [103,113,114,117]. GSK-3 β downregulates the canonical WNT/ β -catenin pathway by inhibiting β -catenin cytosolic stabilization and its translocation in the nucleus [176]. Moreover, several studies have shown a link between neuro-inflammation and the increase of the GSK-3 β activity and in parallel the decrease of the WNT/ β -catenin pathway and the protein kinase B (Akt) pathway [99]. CBD downregulates the expression of GSK-3 β through the promotion of the PI3K/Akt signaling [100,177]. PI3K/Akt signaling regulates GSK-3 β activity [178]. Cannabinoids control the PI3K/Akt/GSK-3 β axis [179,180]. Genes encoding for the PI3K/Akt pathway is increased in CBD-GMSCs (mesenchymal stem cells derived from gingiva treated by CBD) [100].

9.2. Cannabidiol and Oxidative Stress

Energy and glucose metabolisms involved during oxidative stress are mainly controlled by the intracellular FOXO transcription factors (FOXO1, 3a, 4) [128]. The interaction between β -catenin and FOXO transcription factors promotes cell quiescence and cell cycle arrest. β -catenin blocks its transcriptional complex with TCF/LEF through the interaction with FOXO-induced ROS [129]. β -catenin does not translocate to the nucleus and thus accumulates in the cytosol to inactivate the WNT/ β -catenin pathway [130,131].

CBD can reduce the redox balance through the modification of both the level and activity of oxidants and antioxidants [181]. CBD stops the free radical chain reactions through the capture of free radicals and then by reducing their activities [182]. CBD downregulates the oxidative conditions through the prevention of the formation of superoxide radicals, generated by xanthine oxidase (XO), NADPH oxidase (NOX1 and NOX4) [183,184]. Moreover, CBD can enhance the diminution in NO levels in the liver of doxorubicin-treated mice [185]. CBD diminishes reactive oxygen species (ROS) production through the chelation of transition metal ions implicated in the Fenton reaction to form extremely reactive hydroxyl radicals [186]. CBD acts on the classic antioxidant butylated hydroxytoluene (BHT) to prevent the dihydrorodamine oxidation in the Fenton reaction [187].

The antioxidant activity of CBD is characterized by the activation of the redox-sensitive transcription factor which refers to the nuclear reythroid 2-related factor (Nrf2) [188] responsible for the transcription of cytoprotective genes [189]. Superoxide dismutase (SOD) and enzymatic activities of Cu, Zn and Mn-SOD, which are responsible for the metabolism of superoxide radicals, are increased by CBD [190]. Glutathione peroxidase and reductase are increased by CBD and decrease the malonaldehyde (MDA) levels [191]. Enzymatic activities are altered during oxidative modifications of proteins. CBD, by targeting glutathione and cytochrome P450, can inhibit their biological activity to decrease oxidative stress [185,192]. Moreover, through the diminution of ROS levels, CBD can prevent and protect non-enzymatic antioxidants [190], including vitamins A, E and C [193].

9.3. Cannabidiol and Inflammation

Cannabinoids present anti-inflammatory action by endogenous receptors, such as cannabinoid receptor 1 (CB1) and cannabinoid receptor 2 (CB2) [194]. N-Oleoyl glycine (OLGly), a lipoamino acid, increases adipogenic genes including PPAR γ , a marker of inflammation, and the mRNA expression of CB1 receptor. The inhibition of CB1 receptor by its antagonist SR141716 downregulates the actions of OLGly on the expression of PPAR γ .

Moreover, OLGly activates the Akt pathway and inhibits FoxO activity [195]. CBD can bind PPAR γ [162,196]. PPAR γ is a main factor of inflammation by interacting with NF- κ B. This bind occurs between the ligand-binding domain of PPAR γ and the Rel homology domain region of the p65 subunit of NF- κ B. Proteasomal degradation of p65 is caused by Lys48-linked polyubiquitin of the ligand-binding domain of PPAR γ [197]. Thus, PPAR γ can modulate inflammation through the ubiquitination proteasomal degradation of p65 leading to the control of cyclooxygenase (COX2), TNF- α , IL-1 β and IL-6 [162]. PPARs are ligand-activated transcription factors that bind PPRE (PPAR-response elements). PPARs are implicated in numerous pathophysiological mechanisms, such as cell differentiation, protein metabolism, lipid metabolism, carcinogenesis [198,199], adipocyte differentiation, insulin sensitivity and inflammation [200,201]. PPAR γ ligands, such as thiazolidinediones (TZDs), are able to decrease inflammatory activity [202]. Negative crosstalk has been well described between PPAR γ and the WNT pathway [113,203–205]. The PI3K/Akt pathway, which is positively induced by β -catenin [117,204,206–208], acts through the phosphorylation of GSK-3 β to negatively control the PPAR γ expression [209]. PPAR γ agonists decrease β -catenin expression by overactivating GSK-3 β [210]. Moreover, PPAR γ agonists stimulate Dickkopf-1 (DKK1) activity to diminish the canonical WNT/ β -catenin pathway and then downregulate the differentiation of fibroblasts [211]. Moreover, PPAR γ agonists stimulate GSK-3 β to diminish β -catenin expression [210]. In parallel, β -catenin directly inhibits NF- κ B activity [149,150].

9.4. Cannabidiol and Glutamatergic Pathway

Few studies have investigated the interaction between the endogenous cannabinoid system and the glutamatergic pathway in the brain [212]. CBD diminishes the glutamate release in neural signaling implicated in compulsive behavior [213]. Many studies highlighted that the actions of CBD on dopamine and GABA levels were correlated with its strong anti-oxidant properties through the modulation of nitric oxide synthase expression and the inhibition of ROS-generating NADPH oxidases [214]. However, endogenous cannabinoids can bind to the cannabinoid CB1 receptor and dampen presynaptic glutamate release [215]. Moreover, the inhibition of GSK-3 β can decrease EAAT3 activity [82]. Nevertheless, the relation between CBD and the glutamatergic pathway remains unclear. CBD can block the actions of CB1R/CB2 combined receptor agonist [216] and can act as a CB1R antagonist [217].

10. Conclusions

Currently, even if CBs are well documented in the literature, few investigations have studied CBD as a possible alternative therapeutic way to treat glaucoma patients. Nevertheless, CBD could appear to be interesting in glaucoma by targeting both oxidative stress, inflammation and the glutamatergic pathway through the activation of the WNT/ β -catenin pathway. The action of CBD is mainly involved by its negative interaction with GSK-3 β , the main inhibitor of the WNT/ β -catenin pathway. In glaucoma, the WNT/ β -catenin is downregulated to allow the stimulation of oxidative stress, inflammation and glutamatergic pathway. Future prospective studies should focus on CBD and its different actions in glaucoma.

Author Contributions: All authors listed have contributed to the work, and approved it for submit. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Acknowledgments: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.

Abbreviations

GSK-3 β	Glycogen synthase kinase-3 β
LRP 5/6	Low-density lipoprotein receptor-related protein 5/6
NF- κ B	nuclear factor κ B
PPAR γ	Peroxisome proliferator-activated receptor gamma
PI3K-Akt	Phosphatidylinositol 3-kinase-protein kinase B;
TCF/LEF	T-cell factor/lymphoid enhancer factor;
TNF- α	tumor necrosis factor alpha.
MDPI	Multidisciplinary Digital Publishing Institute
DOAJ	Directory of open access journals
TLA	Three letter acronym
LD:	linear dichroism

References

- Laprairie, R.B.; Bagher, A.M.; Kelly, M.E.M.; Denovan-Wright, E.M. Cannabidiol Is a Negative Allosteric Modulator of the Cannabinoid CB1 Receptor. *Br. J. Pharmacol.* **2015**, *172*, 4790–4805. [[CrossRef](#)] [[PubMed](#)]
- Tham, Y.-C.; Li, X.; Wong, T.Y.; Quigley, H.A.; Aung, T.; Cheng, C.-Y. Global Prevalence of Glaucoma and Projections of Glaucoma Burden through 2040: A Systematic Review and Meta-Analysis. *Ophthalmology* **2014**, *121*, 2081–2090. [[CrossRef](#)] [[PubMed](#)]
- Harasymowycz, P.; Birt, C.; Gooi, P.; Heckler, L.; Hutnik, C.; Jinapriya, D.; Shuba, L.; Yan, D.; Day, R. Medical Management of Glaucoma in the 21st Century from a Canadian Perspective. *J. Ophthalmol.* **2016**, *2016*, 6509809. [[CrossRef](#)]
- Stein, J.D.; Khawaja, A.P.; Weizer, J.S. Glaucoma in Adults—Screening, Diagnosis, and Management: A Review. *JAMA* **2021**, *325*, 164–174. [[CrossRef](#)] [[PubMed](#)]
- Esporcatte, B.L.B.; Tavares, I.M. Normal-Tension Glaucoma: An Update. *Arq. Bras. Oftalmol.* **2016**, *79*, 270–276. [[CrossRef](#)]
- Allison, K.; Patel, D.; Alabi, O. Epidemiology of Glaucoma: The Past, Present, and Predictions for the Future. *Cureus* **2020**, *12*, e11686. [[CrossRef](#)]
- Grzybowski, A.; Och, M.; Kanclerz, P.; Leffler, C.; Moraes, C.G.D. Primary Open Angle Glaucoma and Vascular Risk Factors: A Review of Population Based Studies from 1990 to 2019. *J. Clin. Med.* **2020**, *9*, 761. [[CrossRef](#)]
- Shields, M.B. Normal-Tension Glaucoma: Is It Different from Primary Open-Angle Glaucoma? *Curr. Opin. Ophthalmol.* **2008**, *19*, 85–88. [[CrossRef](#)]
- Saccà, S.C.; Gandolfi, S.; Bagnis, A.; Manni, G.; Damonte, G.; Traverso, C.E.; Izzotti, A. From DNA Damage to Functional Changes of the Trabecular Meshwork in Aging and Glaucoma. *Ageing Res. Rev.* **2016**, *29*, 26–41. [[CrossRef](#)]
- Chrysostomou, V.; Rezanian, F.; Trounce, I.A.; Crowston, J.G. Oxidative Stress and Mitochondrial Dysfunction in Glaucoma. *Curr. Opin. Pharmacol.* **2013**, *13*, 12–15. [[CrossRef](#)]
- Vohra, R.; Dalgaard, L.M.; Vibaek, J.; Langbøl, M.A.; Bergersen, L.H.; Olsen, N.V.; Hassel, B.; Chaudhry, F.A.; Kolko, M. Potential Metabolic Markers in Glaucoma and Their Regulation in Response to Hypoxia. *Acta Ophthalmol.* **2019**, *97*, 567–576. [[CrossRef](#)]
- Lebrun-Julien, F.; Duplan, L.; Pernet, V.; Osswald, I.; Sapieha, P.; Bourgeois, P.; Dickson, K.; Bowie, D.; Barker, P.A.; Di Polo, A. Excitotoxic Death of Retinal Neurons in Vivo Occurs via a Non-Cell-Autonomous Mechanism. *J. Neurosci. Off. J. Soc. Neurosci.* **2009**, *29*, 5536–5545. [[CrossRef](#)]
- Williams, P.A.; Marsh-Armstrong, N.; Howell, G.R. Lasker/IRRF Initiative on Astrocytes and Glaucomatous Neurodegeneration Participants Neuroinflammation in Glaucoma: A New Opportunity. *Exp. Eye Res.* **2017**, *157*, 20–27. [[CrossRef](#)]
- Jiang, S.; Kametani, M.; Chen, D.F. Adaptive Immunity: New Aspects of Pathogenesis Underlying Neurodegeneration in Glaucoma and Optic Neuropathy. *Front. Immunol.* **2020**, *11*, 65. [[CrossRef](#)]
- Eells, J.T. Mitochondrial Dysfunction in the Aging Retina. *Biology* **2019**, *8*, 31. [[CrossRef](#)]
- Sreekumar, P.G.; Hinton, D.R.; Kannan, R. The Emerging Role of Senescence in Ocular Disease. *Oxid. Med. Cell. Longev.* **2020**, *2020*, 2583601. [[CrossRef](#)] [[PubMed](#)]
- Xu, H.; Chen, M. Targeting the Complement System for the Management of Retinal Inflammatory and Degenerative Diseases. *Eur. J. Pharmacol.* **2016**, *787*, 94–104. [[CrossRef](#)]
- Medzhitov, R. Origin and Physiological Roles of Inflammation. *Nature* **2008**, *454*, 428–435. [[CrossRef](#)] [[PubMed](#)]
- Chen, M.; Luo, C.; Zhao, J.; Devarajan, G.; Xu, H. Immune Regulation in the Aging Retina. *Prog. Retin. Eye Res.* **2019**, *69*, 159–172. [[CrossRef](#)]
- Johnson, M. “What Controls Aqueous Humour Outflow Resistance?”. *Exp. Eye Res.* **2006**, *82*, 545–557. [[CrossRef](#)]
- Knepper, P.A.; Goossens, W.; Hvizd, M.; Palmberg, P.F. Glycosaminoglycans of the Human Trabecular Meshwork in Primary Open-Angle Glaucoma. *Investig. Ophthalmol. Vis. Sci.* **1996**, *37*, 1360–1367.
- Wang, X.; Huai, G.; Wang, H.; Liu, Y.; Qi, P.; Shi, W.; Peng, J.; Yang, H.; Deng, S.; Wang, Y. Mutual Regulation of the Hippo/Wnt/LPA/TGF- β Signaling Pathways and Their Roles in Glaucoma (Review). *Int. J. Mol. Med.* **2018**, *41*, 1201–1212. [[CrossRef](#)] [[PubMed](#)]

23. Hepler, R.S.; Frank, I.R. Marijuana Smoking and Intraocular Pressure. *JAMA* **1971**, *217*, 1392. [[CrossRef](#)]
24. Aghazadeh Tabrizi, M.; Baraldi, P.G.; Borea, P.A.; Varani, K. Medicinal Chemistry, Pharmacology, and Potential Therapeutic Benefits of Cannabinoid CB2 Receptor Agonists. *Chem. Rev.* **2016**, *116*, 519–560. [[CrossRef](#)] [[PubMed](#)]
25. Cairns, E.A.; Baldrige, W.H.; Kelly, M.E.M. The Endocannabinoid System as a Therapeutic Target in Glaucoma. *Neural Plast.* **2016**, *2016*, 9364091. [[CrossRef](#)]
26. Miller, S.; Daily, L.; Dharla, V.; Gertsch, J.; Malamas, M.S.; Ojima, I.; Kaczocha, M.; Ogasawara, D.; Straiker, A. Endocannabinoid Metabolism and Transport as Targets to Regulate Intraocular Pressure. *Exp. Eye Res.* **2020**, *201*, 108266. [[CrossRef](#)]
27. Passani, A.; Posarelli, C.; Sframeli, A.T.; Perciballi, L.; Pellegrini, M.; Guidi, G.; Figus, M. Cannabinoids in Glaucoma Patients: The Never-Ending Story. *J. Clin. Med.* **2020**, *9*, 3978. [[CrossRef](#)] [[PubMed](#)]
28. Stasiłowicz, A.; Tomala, A.; Podolak, I.; Cielecka-Piontek, J. Cannabis Sativa L. as a Natural Drug Meeting the Criteria of a Multitarget Approach to Treatment. *Int. J. Mol. Sci.* **2021**, *22*, 778. [[CrossRef](#)] [[PubMed](#)]
29. Marsicano, G.; Goodenough, S.; Monory, K.; Hermann, H.; Eder, M.; Cannich, A.; Azad, S.C.; Cascio, M.G.; Gutiérrez, S.O.; van der Stelt, M.; et al. CB1 Cannabinoid Receptors and On-Demand Defense against Excitotoxicity. *Science* **2003**, *302*, 84–88. [[CrossRef](#)]
30. Lax, P.; Esquivá, G.; Altavilla, C.; Cuenca, N. Neuroprotective Effects of the Cannabinoid Agonist HU210 on Retinal Degeneration. *Exp. Eye Res.* **2014**, *120*, 175–185. [[CrossRef](#)]
31. Izzo, A.A.; Borrelli, F.; Capasso, R.; Di Marzo, V.; Mechoulam, R. Non-Psychotropic Plant Cannabinoids: New Therapeutic Opportunities from an Ancient Herb. *Trends Pharmacol. Sci.* **2009**, *30*, 515–527. [[CrossRef](#)]
32. Campos, A.C.; Moreira, F.A.; Gomes, F.V.; Del Bel, E.A.; Guimarães, F.S. Multiple Mechanisms Involved in the Large-Spectrum Therapeutic Potential of Cannabidiol in Psychiatric Disorders. *Philos. Trans. R. Soc. Lond. B Biol. Sci.* **2012**, *367*, 3364–3378. [[CrossRef](#)] [[PubMed](#)]
33. Schier, A.R.D.M.; Ribeiro, N.P.D.O.; Hallak, J.E.C.; Crippa, J.A.S.; Nardi, A.E.; Zuardi, A.W. Cannabidiol, a Cannabis Sativa Constituent, as an Anxiolytic Drug. *Rev. Bras. Psiquiatr. Sao Paulo Braz.* **1999** *2012*, *34* (Suppl. 1), S104–S110. [[CrossRef](#)]
34. Micale, V.; Di Marzo, V.; Sulcova, A.; Wotjak, C.T.; Drago, F. Endocannabinoid System and Mood Disorders: Priming a Target for New Therapies. *Pharmacol. Ther.* **2013**, *138*, 18–37. [[CrossRef](#)]
35. De Mello Schier, A.R.; de Oliveira Ribeiro, N.P.; Coutinho, D.S.; Machado, S.; Arias-Carrión, O.; Crippa, J.A.; Zuardi, A.W.; Nardi, A.E.; Silva, A.C. Antidepressant-like and Anxiolytic-like Effects of Cannabidiol: A Chemical Compound of Cannabis Sativa. *CNS Neurol. Disord. Drug Targets* **2014**, *13*, 953–960. [[CrossRef](#)] [[PubMed](#)]
36. Wilson, R.I.; Nicoll, R.A. Endocannabinoid Signaling in the Brain. *Science* **2002**, *296*, 678–682. [[CrossRef](#)] [[PubMed](#)]
37. Castillo, P.E.; Younts, T.J.; Chávez, A.E.; Hashimoto, Y. Endocannabinoid Signaling and Synaptic Function. *Neuron* **2012**, *76*, 70–81. [[CrossRef](#)]
38. Silvestri, C.; Di Marzo, V. The Endocannabinoid System in Energy Homeostasis and the Etiopathology of Metabolic Disorders. *Cell Metab.* **2013**, *17*, 475–490. [[CrossRef](#)] [[PubMed](#)]
39. Raja, A.; Ahmadi, S.; de Costa, F.; Li, N.; Kerman, K. Attenuation of Oxidative Stress by Cannabinoids and Cannabis Extracts in Differentiated Neuronal Cells. *Pharm. Basel Switz.* **2020**, *13*, 328. [[CrossRef](#)]
40. El-Remessy, A.B.; Khalil, I.E.; Matragoon, S.; Abou-Mohamed, G.; Tsai, N.-J.; Roon, P.; Caldwell, R.B.; Caldwell, R.W.; Green, K.; Liou, G.I. Neuroprotective Effect of (-)-Delta9-Tetrahydrocannabinol and Cannabidiol in N-Methyl-D-Aspartate-Induced Retinal Neurotoxicity: Involvement of Peroxynitrite. *Am. J. Pathol.* **2003**, *163*, 1997–2008. [[CrossRef](#)]
41. Alvarado, J.; Murphy, C.; Juster, R. Trabecular Meshwork Cellularity in Primary Open-Angle Glaucoma and Nonglaucomatous Normals. *Ophthalmology* **1984**, *91*, 564–579. [[CrossRef](#)]
42. Vernazza, S.; Tirendi, S.; Scarfi, S.; Passalacqua, M.; Oddone, F.; Traverso, C.E.; Rizzato, I.; Bassi, A.M.; Saccà, S.C. 2D- and 3D-Cultures of Human Trabecular Meshwork Cells: A Preliminary Assessment of an in Vitro Model for Glaucoma Study. *PLoS ONE* **2019**, *14*, e0221942. [[CrossRef](#)]
43. Vernazza, S.; Tirendi, S.; Bassi, A.M.; Traverso, C.E.; Saccà, S.C. Neuroinflammation in Primary Open-Angle Glaucoma. *J. Clin. Med.* **2020**, *9*, 3172. [[CrossRef](#)]
44. Castro, A.; Du, Y. Trabecular Meshwork Regeneration—A Potential Treatment for Glaucoma. *Curr. Ophthalmol. Rep.* **2019**, *7*, 80–88. [[CrossRef](#)]
45. Alvarado, J.A.; Alvarado, R.G.; Yeh, R.F.; Franse-Carman, L.; Marcellino, G.R.; Brownstein, M.J. A New Insight into the Cellular Regulation of Aqueous Outflow: How Trabecular Meshwork Endothelial Cells Drive a Mechanism That Regulates the Permeability of Schlemm’s Canal Endothelial Cells. *Br. J. Ophthalmol.* **2005**, *89*, 1500–1505. [[CrossRef](#)] [[PubMed](#)]
46. Saccà, S.C.; Gandolfi, S.; Bagnis, A.; Manni, G.; Damonte, G.; Traverso, C.E.; Izzotti, A. The Outflow Pathway: A Tissue with Morphological and Functional Unity. *J. Cell. Physiol.* **2016**, *231*, 1876–1893. [[CrossRef](#)] [[PubMed](#)]
47. Izzotti, A.; Saccà, S.C.; Longobardi, M.; Cartiglia, C. Sensitivity of Ocular Anterior Chamber Tissues to Oxidative Damage and Its Relevance to the Pathogenesis of Glaucoma. *Investig. Ophthalmol. Vis. Sci.* **2009**, *50*, 5251–5258. [[CrossRef](#)] [[PubMed](#)]
48. Saccà, S.C.; Tirendi, S.; Scarfi, S.; Passalacqua, M.; Oddone, F.; Traverso, C.E.; Vernazza, S.; Bassi, A.M. An Advanced in Vitro Model to Assess Glaucoma Onset. *ALTEX* **2020**, *37*, 265–274. [[CrossRef](#)]
49. Liton, P.B.; Lin, Y.; Luna, C.; Li, G.; Gonzalez, P.; Epstein, D.L. Cultured Porcine Trabecular Meshwork Cells Display Altered Lysosomal Function When Subjected to Chronic Oxidative Stress. *Investig. Ophthalmol. Vis. Sci.* **2008**, *49*, 3961–3969. [[CrossRef](#)]

50. Liton, P.B.; Challa, P.; Stinnett, S.; Luna, C.; Epstein, D.L.; Gonzalez, P. Cellular Senescence in the Glaucomatous Outflow Pathway. *Exp. Gerontol.* **2005**, *40*, 745–748. [[CrossRef](#)]
51. Salinas-Navarro, M.; Alarcón-Martínez, L.; Valiente-Soriano, F.J.; Jiménez-López, M.; Mayor-Torroglosa, S.; Avilés-Trigueros, M.; Villegas-Pérez, M.P.; Vidal-Sanz, M. Ocular Hypertension Impairs Optic Nerve Axonal Transport Leading to Progressive Retinal Ganglion Cell Degeneration. *Exp. Eye Res.* **2010**, *90*, 168–183. [[CrossRef](#)]
52. Ju, W.-K.; Kim, K.-Y.; Lindsey, J.D.; Angert, M.; Patel, A.; Scott, R.T.; Liu, Q.; Crowston, J.G.; Ellisman, M.H.; Perkins, G.A.; et al. Elevated Hydrostatic Pressure Triggers Release of OPA1 and Cytochrome C, and Induces Apoptotic Cell Death in Differentiated RGC-5 Cells. *Mol. Vis.* **2009**, *15*, 120–134. [[PubMed](#)]
53. McMonnies, C.W. Glaucoma History and Risk Factors. *J. Optom.* **2017**, *10*, 71–78. [[CrossRef](#)] [[PubMed](#)]
54. Mahajan, N.; Arora, P.; Sandhir, R. Perturbed Biochemical Pathways and Associated Oxidative Stress Lead to Vascular Dysfunctions in Diabetic Retinopathy. *Oxid. Med. Cell. Longev.* **2019**, *2019*, 8458472. [[CrossRef](#)]
55. Pawlowska, E.; Szczepanska, J.; Koskela, A.; Kaarniranta, K.; Blasiak, J. Dietary Polyphenols in Age-Related Macular Degeneration: Protection against Oxidative Stress and Beyond. *Oxid. Med. Cell. Longev.* **2019**, *2019*, 9682318. [[CrossRef](#)]
56. Crabtree, M.J.; Channon, K.M. Synthesis and Recycling of Tetrahydrobiopterin in Endothelial Function and Vascular Disease. *Nitric Oxide Biol. Chem.* **2011**, *25*, 81–88. [[CrossRef](#)]
57. Mozaffarieh, M.; Flammer, J. New Insights in the Pathogenesis and Treatment of Normal Tension Glaucoma. *Curr. Opin. Pharmacol.* **2013**, *13*, 43–49. [[CrossRef](#)] [[PubMed](#)]
58. Benoist d’Azy, C.; Pereira, B.; Chiambaretta, F.; Dutheil, F. Oxidative and Anti-Oxidative Stress Markers in Chronic Glaucoma: A Systematic Review and Meta-Analysis. *PLoS ONE* **2016**, *11*, e0166915. [[CrossRef](#)]
59. Gericke, A.; Mann, C.; Zadeh, J.K.; Musayeva, A.; Wolff, I.; Wang, M.; Pfeiffer, N.; Daiber, A.; Li, H.; Xia, N.; et al. Elevated Intraocular Pressure Causes Abnormal Reactivity of Mouse Retinal Arterioles. *Oxid. Med. Cell. Longev.* **2019**, *2019*, 9736047. [[CrossRef](#)]
60. Salt, T.E.; Cordeiro, M.F. Glutamate Excitotoxicity in Glaucoma: Throwing the Baby out with the Bathwater? *Eye Lond. Engl.* **2006**, *20*, 730–731. [[CrossRef](#)]
61. Tezel, G.; Yang, X.; Luo, C.; Peng, Y.; Sun, S.L.; Sun, D. Mechanisms of Immune System Activation in Glaucoma: Oxidative Stress-Stimulated Antigen Presentation by the Retina and Optic Nerve Head Glia. *Investig. Ophthalmol. Vis. Sci.* **2007**, *48*, 705–714. [[CrossRef](#)] [[PubMed](#)]
62. Tezel, G.; Wax, M.B. Increased Production of Tumor Necrosis Factor-Alpha by Glial Cells Exposed to Simulated Ischemia or Elevated Hydrostatic Pressure Induces Apoptosis in Cocultured Retinal Ganglion Cells. *J. Neurosci. Off. J. Soc. Neurosci.* **2000**, *20*, 8693–8700. [[CrossRef](#)]
63. Lin, W.-W.; Karin, M. A Cytokine-Mediated Link between Innate Immunity, Inflammation, and Cancer. *J. Clin. Investig.* **2007**, *117*, 1175–1183. [[CrossRef](#)]
64. Sobolewski, C.; Cerella, C.; Dicato, M.; Ghibelli, L.; Diederich, M. The Role of Cyclooxygenase-2 in Cell Proliferation and Cell Death in Human Malignancies. *Int. J. Cell Biol.* **2010**, *2010*, 215158. [[CrossRef](#)]
65. Lu, H.; Ouyang, W.; Huang, C. Inflammation, a Key Event in Cancer Development. *Mol. Cancer Res. MCR* **2006**, *4*, 221–233. [[CrossRef](#)]
66. Federico, A.; Morgillo, F.; Tuccillo, C.; Ciardiello, F.; Loguercio, C. Chronic Inflammation and Oxidative Stress in Human Carcinogenesis. *Int. J. Cancer* **2007**, *121*, 2381–2386. [[CrossRef](#)]
67. Wu, Y.; Antony, S.; Meitzler, J.L.; Doroshow, J.H. Molecular Mechanisms Underlying Chronic Inflammation-Associated Cancers. *Cancer Lett.* **2014**, *345*, 164–173. [[CrossRef](#)]
68. Bubici, C.; Papa, S.; Pham, C.G.; Zazzeroni, F.; Franzoso, G. The NF-KappaB-Mediated Control of ROS and JNK Signaling. *Histol. Histopathol.* **2006**, *21*, 69–80. [[CrossRef](#)] [[PubMed](#)]
69. Kim, Y.-H.; Woo, K.J.; Lim, J.H.; Kim, S.; Lee, T.J.; Jung, E.M.; Lee, J.-M.; Park, J.-W.; Kwon, T.K. 8-Hydroxyquinoline Inhibits iNOS Expression and Nitric Oxide Production by down-Regulating LPS-Induced Activity of NF-KappaB and C/EBPbeta in Raw 264.7 Cells. *Biochem. Biophys. Res. Commun.* **2005**, *329*, 591–597. [[CrossRef](#)]
70. Reuter, S.; Gupta, S.C.; Chaturvedi, M.M.; Aggarwal, B.B. Oxidative Stress, Inflammation, and Cancer: How Are They Linked? *Free Radic. Biol. Med.* **2010**, *49*, 1603–1616. [[CrossRef](#)]
71. Duracková, Z. Some Current Insights into Oxidative Stress. *Physiol. Res.* **2010**, *59*, 459–469. [[CrossRef](#)]
72. Debnath, T.; Kim, D.H.; Lim, B.O. Natural Products as a Source of Anti-Inflammatory Agents Associated with Inflammatory Bowel Disease. *Mol. Basel Switz.* **2013**, *18*, 7253–7270. [[CrossRef](#)]
73. Giudice, A.; Montella, M. Activation of the Nrf2-ARE Signaling Pathway: A Promising Strategy in Cancer Prevention. *BioEssays News Rev. Mol. Cell. Dev. Biol.* **2006**, *28*, 169–181. [[CrossRef](#)]
74. Lin, M.; Zhai, X.; Wang, G.; Tian, X.; Gao, D.; Shi, L.; Wu, H.; Fan, Q.; Peng, J.; Liu, K.; et al. Salvianolic Acid B Protects against Acetaminophen Hepatotoxicity by Inducing Nrf2 and Phase II Detoxification Gene Expression via Activation of the PI3K and PKC Signaling Pathways. *J. Pharmacol. Sci.* **2015**, *127*, 203–210. [[CrossRef](#)]
75. Dey, A.; Lakshmanan, J. The Role of Antioxidants and Other Agents in Alleviating Hyperglycemia Mediated Oxidative Stress and Injury in Liver. *Food Funct.* **2013**, *4*, 1148–1184. [[CrossRef](#)] [[PubMed](#)]
76. Ting, J.T.; Feng, G. Neurobiology of Obsessive-Compulsive Disorder: Insights into Neural Circuitry Dysfunction through Mouse Genetics. *Curr. Opin. Neurobiol.* **2011**, *21*, 842–848. [[CrossRef](#)]

77. Javitt, D.C.; Schoepp, D.; Kalivas, P.W.; Volkow, N.D.; Zarate, C.; Merchant, K.; Bear, M.F.; Umbricht, D.; Hajos, M.; Potter, W.Z.; et al. Translating Glutamate: From Pathophysiology to Treatment. *Sci. Transl. Med.* **2011**, *3*, 102mr2. [[CrossRef](#)]
78. Sanacora, G.; Zarate, C.A.; Krystal, J.H.; Manji, H.K. Targeting the Glutamatergic System to Develop Novel, Improved Therapeutics for Mood Disorders. *Nat. Rev. Drug Discov.* **2008**, *7*, 426–437. [[CrossRef](#)]
79. Arnold, P.D.; Sicard, T.; Burroughs, E.; Richter, M.A.; Kennedy, J.L. Glutamate Transporter Gene SLC1A1 Associated with Obsessive-Compulsive Disorder. *Arch. Gen. Psychiatry* **2006**, *63*, 769–776. [[CrossRef](#)]
80. Daikhin, Y.; Yudkoff, M. Compartmentation of Brain Glutamate Metabolism in Neurons and Glia. *J. Nutr.* **2000**, *130*, 1026S–1031S. [[CrossRef](#)]
81. Scimemi, A.; Tian, H.; Diamond, J.S. Neuronal Transporters Regulate Glutamate Clearance, NMDA Receptor Activation, and Synaptic Plasticity in the Hippocampus. *J. Neurosci. Off. J. Soc. Neurosci.* **2009**, *29*, 14581–14595. [[CrossRef](#)]
82. Wu, K.; Hanna, G.L.; Rosenberg, D.R.; Arnold, P.D. The Role of Glutamate Signaling in the Pathogenesis and Treatment of Obsessive-Compulsive Disorder. *Pharmacol. Biochem. Behav.* **2012**, *100*, 726–735. [[CrossRef](#)]
83. Kim, M.-S.; Shutov, L.P.; Gnanasekaran, A.; Lin, Z.; Rysted, J.E.; Ulrich, J.D.; Usachev, Y.M. Nerve Growth Factor (NGF) Regulates Activity of Nuclear Factor of Activated T-Cells (NFAT) in Neurons via the Phosphatidylinositol 3-Kinase (PI3K)-Akt-Glycogen Synthase Kinase 3 β (GSK3 β) Pathway. *J. Biol. Chem.* **2014**, *289*, 31349–31360. [[CrossRef](#)]
84. Lotery, A.J. Glutamate Excitotoxicity in Glaucoma: Truth or Fiction? *Eye Lond. Engl.* **2005**, *19*, 369–370. [[CrossRef](#)]
85. Seki, M.; Lipton, S.A. Targeting Excitotoxic/Free Radical Signaling Pathways for Therapeutic Intervention in Glaucoma. *Prog. Brain Res.* **2008**, *173*, 495–510. [[CrossRef](#)]
86. Lee, D.; Shim, M.S.; Kim, K.-Y.; Noh, Y.H.; Kim, H.; Kim, S.Y.; Weinreb, R.N.; Ju, W.-K. Coenzyme Q10 Inhibits Glutamate Excitotoxicity and Oxidative Stress-Mediated Mitochondrial Alteration in a Mouse Model of Glaucoma. *Investig. Ophthalmol. Vis. Sci.* **2014**, *55*, 993–1005. [[CrossRef](#)]
87. Siliprandi, R.; Canella, R.; Carmignoto, G.; Schiavo, N.; Zanellato, A.; Zannoni, R.; Vantini, G. N-Methyl-D-Aspartate-Induced Neurotoxicity in the Adult Rat Retina. *Vis. Neurosci.* **1992**, *8*, 567–573. [[CrossRef](#)] [[PubMed](#)]
88. Loh, K.M.; van Amerongen, R.; Nusse, R. Generating Cellular Diversity and Spatial Form: Wnt Signaling and the Evolution of Multicellular Animals. *Dev. Cell* **2016**, *38*, 643–655. [[CrossRef](#)]
89. Oren, O.; Smith, B.D. Eliminating Cancer Stem Cells by Targeting Embryonic Signaling Pathways. *Stem Cell Rev.* **2017**, *13*, 17–23. [[CrossRef](#)]
90. Al-Harathi, L. Wnt/ β -Catenin and Its Diverse Physiological Cell Signaling Pathways in Neurodegenerative and Neuropsychiatric Disorders. *J. Neuroimmune Pharmacol.* **2012**, *7*, 725–730. [[CrossRef](#)]
91. Marchetti, B.; Pluchino, S. Wnt Your Brain Be Inflamed? Yes, It Wnt! *Trends Mol. Med.* **2013**, *19*, 144–156. [[CrossRef](#)]
92. Lecarpentier, Y.; Claes, V.; Duthoit, G.; Hébert, J.-L. Circadian Rhythms, Wnt/Beta-Catenin Pathway and PPAR Alpha/Gamma Profiles in Diseases with Primary or Secondary Cardiac Dysfunction. *Front. Physiol.* **2014**, *5*, 429. [[CrossRef](#)]
93. Lecarpentier, Y.; Vallée, A. Opposite Interplay between PPAR Gamma and Canonical Wnt/Beta-Catenin Pathway in Amyotrophic Lateral Sclerosis. *Front. Neurol.* **2016**, *7*, 100. [[CrossRef](#)]
94. Vallée, A.; Lecarpentier, Y. Alzheimer Disease: Crosstalk between the Canonical Wnt/Beta-Catenin Pathway and PPARs Alpha and Gamma. *Front. Neurosci.* **2016**, *10*, 459. [[CrossRef](#)]
95. Vallée, A.; Lecarpentier, Y.; Guillevin, R.; Vallée, J.-N. Thermodynamics in Neurodegenerative Diseases: Interplay Between Canonical WNT/Beta-Catenin Pathway-PPAR Gamma, Energy Metabolism and Circadian Rhythms. *Neuromolecular Med.* **2018**, *20*, 174–204. [[CrossRef](#)] [[PubMed](#)]
96. Vallée, A.; Vallée, J.-N.; Lecarpentier, Y. Parkinson's Disease: Potential Actions of Lithium by Targeting the WNT/ β -Catenin Pathway, Oxidative Stress, Inflammation and Glutamatergic Pathway. *Cells* **2021**, *10*, 230. [[CrossRef](#)] [[PubMed](#)]
97. He, T.C.; Sparks, A.B.; Rago, C.; Hermeking, H.; Zawel, L.; da Costa, L.T.; Morin, P.J.; Vogelstein, B.; Kinzler, K.W. Identification of C-MYC as a Target of the APC Pathway. *Science* **1998**, *281*, 1509–1512. [[CrossRef](#)] [[PubMed](#)]
98. Shtutman, M.; Zhurinsky, J.; Simcha, I.; Albanese, C.; D'Amico, M.; Pestell, R.; Ben-Ze'ev, A. The Cyclin D1 Gene Is a Target of the Beta-Catenin/LEF-1 Pathway. *Proc. Natl. Acad. Sci. USA* **1999**, *96*, 5522–5527. [[CrossRef](#)] [[PubMed](#)]
99. Angers, S.; Moon, R.T. Proximal Events in Wnt Signal Transduction. *Nat. Rev. Mol. Cell Biol.* **2009**. [[CrossRef](#)] [[PubMed](#)]
100. Sharma, C.; Pradeep, A.; Wong, L.; Rana, A.; Rana, B. Peroxisome Proliferator-Activated Receptor Gamma Activation Can Regulate Beta-Catenin Levels via a Proteasome-Mediated and Adenomatous Polyposis Coli-Independent Pathway. *J. Biol. Chem.* **2004**, *279*, 35583–35594. [[CrossRef](#)]
101. Rosi, M.C.; Luccarini, I.; Grossi, C.; Fiorentini, A.; Spillantini, M.G.; Prisco, A.; Scali, C.; Gianfriddo, M.; Caricasole, A.; Terstappen, G.C.; et al. Increased Dickkopf-1 Expression in Transgenic Mouse Models of Neurodegenerative Disease. *J. Neurochem.* **2010**, *112*, 1539–1551. [[CrossRef](#)]
102. Clevers, H.; Nusse, R. Wnt/ β -Catenin Signaling and Disease. *Cell* **2012**, *149*, 1192–1205. [[CrossRef](#)] [[PubMed](#)]
103. Inestrosa, N.C.; Montecinos-Oliva, C.; Fuenzalida, M. Wnt Signaling: Role in Alzheimer Disease and Schizophrenia. *J. Neuroimmune Pharmacol. Off. J. Soc. Neuroimmune Pharmacol.* **2012**, *7*, 788–807. [[CrossRef](#)]
104. Vallée, A.; Lecarpentier, Y.; Guillevin, R.; Vallée, J.-N. Interactions between TGF- β 1, Canonical WNT/ β -Catenin Pathway and PPAR γ in Radiation-Induced Fibrosis. *Oncotarget* **2017**, *8*, 90579–90604. [[CrossRef](#)]
105. Vallée, A.; Lecarpentier, Y.; Vallée, J.-N. Hypothesis of Opposite Interplay Between the Canonical WNT/Beta-Catenin Pathway and PPAR Gamma in Primary Central Nervous System Lymphomas. *Curr. Issues Mol. Biol.* **2019**, *31*, 1–20. [[CrossRef](#)]

106. Aberle, H.; Bauer, A.; Stappert, J.; Kispert, A.; Kemler, R. β -Catenin Is a Target for the Ubiquitin–Proteasome Pathway. *EMBO J.* **1997**, *16*, 3797–3804. [[CrossRef](#)]
107. Wu, D.; Pan, W. GSK3: A Multifaceted Kinase in Wnt Signaling. *Trends Biochem. Sci.* **2010**, *35*, 161–168. [[CrossRef](#)]
108. Hur, E.-M.; Zhou, F.-Q. GSK3 Signalling in Neural Development. *Nat. Rev. Neurosci.* **2010**, *11*, 539–551. [[CrossRef](#)]
109. Ambacher, K.K.; Pitzul, K.B.; Karajgikar, M.; Hamilton, A.; Ferguson, S.S.; Cregan, S.P. The JNK-and AKT/GSK3 β - Signaling Pathways Converge to Regulate Puma Induction and Neuronal Apoptosis Induced by Trophic Factor Deprivation. *PLoS ONE* **2012**, *7*, e46885. [[CrossRef](#)] [[PubMed](#)]
110. Orellana, A.M.M.; Vasconcelos, A.R.; Leite, J.A.; de Sá Lima, L.; Andreotti, D.Z.; Munhoz, C.D.; Kawamoto, E.M.; Scavone, C. Age-Related Neuroinflammation and Changes in AKT-GSK-3 β and WNT/ β -CATENIN Signaling in Rat Hippocampus. *Aging* **2015**, *7*, 1094–1111. [[CrossRef](#)] [[PubMed](#)]
111. Wu, J.-H.; Zhang, S.-H.; Gao, F.-J.; Lei, Y.; Chen, X.-Y.; Gao, F.; Zhang, S.-J.; Sun, X.-H. RNAi Screening Identifies GSK3 β as a Regulator of DRP1 and the Neuroprotection of Lithium Chloride against Elevated Pressure Involved in Downregulation of DRP1. *Neurosci. Lett.* **2013**, *554*, 99–104. [[CrossRef](#)]
112. Russo, R.; Adornetto, A.; Cavaliere, F.; Varano, G.P.; Rusciano, D.; Morrone, L.A.; Corasaniti, M.T.; Bagetta, G.; Nucci, C. Intravitreal Injection of Forskolol, Homotaurine, and L-Carnosine Affords Neuroprotection to Retinal Ganglion Cells Following Retinal Ischemic Injury. *Mol. Vis.* **2015**, *21*, 718–729.
113. Giese, K.P. GSK-3: A Key Player in Neurodegeneration and Memory. *IUBMB Life* **2009**, *61*, 516–521. [[CrossRef](#)]
114. Vallée, A.; Vallée, J.-N.; Lecarpentier, Y. PPAR γ Agonists: Potential Treatment for Autism Spectrum Disorder by Inhibiting the Canonical WNT/ β -Catenin Pathway. *Mol. Psychiatry* **2018**. [[CrossRef](#)]
115. Vallée, A.; Lecarpentier, Y.; Vallée, J.-N. Targeting the Canonical WNT/ β -Catenin Pathway in Cancer Treatment Using Non-Steroidal Anti-Inflammatory Drugs. *Cells* **2019**, *8*, 726. [[CrossRef](#)]
116. Vallée, A.; Lecarpentier, Y.; Guillevin, R.; Vallée, J.-N. The Influence of Circadian Rhythms and Aerobic Glycolysis in Autism Spectrum Disorder. *Transl. Psychiatry* **2020**, *10*, 400. [[CrossRef](#)]
117. Vallée, A.; Vallée, J.-N.; Guillevin, R.; Lecarpentier, Y. Riluzole: A Therapeutic Strategy in Alzheimer’s Disease by Targeting the WNT/ β -Catenin Pathway. *Aging* **2020**, *12*, 3095–3113. [[CrossRef](#)]
118. Vallée, A.; Vallée, J.-N. Warburg Effect Hypothesis in Autism Spectrum Disorders. *Mol. Brain* **2018**, *11*. [[CrossRef](#)]
119. Mao, W.; Millar, J.C.; Wang, W.-H.; Silverman, S.M.; Liu, Y.; Wordinger, R.J.; Rubin, J.S.; Pang, I.-H.; Clark, A.F. Existence of the Canonical Wnt Signaling Pathway in the Human Trabecular Meshwork. *Investig. Ophthalmol. Vis. Sci.* **2012**, *53*, 7043–7051. [[CrossRef](#)]
120. Wang, W.-H.; McNatt, L.G.; Pang, I.-H.; Millar, J.C.; Hellberg, P.E.; Hellberg, M.H.; Steely, H.T.; Rubin, J.S.; Fingert, J.H.; Sheffield, V.C.; et al. Increased Expression of the WNT Antagonist SFRP-1 in Glaucoma Elevates Intraocular Pressure. *J. Clin. Investig.* **2008**, *118*, 1056–1064. [[CrossRef](#)]
121. Morgan, J.T.; Raghunathan, V.K.; Chang, Y.-R.; Murphy, C.J.; Russell, P. Wnt Inhibition Induces Persistent Increases in Intrinsic Stiffness of Human Trabecular Meshwork Cells. *Exp. Eye Res.* **2015**, *132*, 174–178. [[CrossRef](#)] [[PubMed](#)]
122. Kwon, H.-S.; Lee, H.-S.; Ji, Y.; Rubin, J.S.; Tomarev, S.I. Myocilin Is a Modulator of Wnt Signaling. *Mol. Cell. Biol.* **2009**, *29*, 2139–2154. [[CrossRef](#)] [[PubMed](#)]
123. Atienzar-Aroca, R.; Aroca-Aguilar, J.-D.; Alexandre-Moreno, S.; Ferre-Fernández, J.-J.; Bonet-Fernández, J.-M.; Cabañero-Varela, M.-J.; Escribano, J. Knockout of Myoc Provides Evidence for the Role of Myocilin in Zebrafish Sex Determination Associated with Wnt Signalling Downregulation. *Biology* **2021**, *10*, 98. [[CrossRef](#)]
124. Lerner, N.; Chen, I.; Schreiber-Avissar, S.; Beit-Yannai, E. Extracellular Vesicles Mediate Anti-Oxidative Response-In Vitro Study in the Ocular Drainage System. *Int. J. Mol. Sci.* **2020**, *21*, 6105. [[CrossRef](#)]
125. Dhamodaran, K.; Baidouri, H.; Sandoval, L.; Raghunathan, V. Wnt Activation After Inhibition Restores Trabecular Meshwork Cells Toward a Normal Phenotype. *Investig. Ophthalmol. Vis. Sci.* **2020**, *61*, 30. [[CrossRef](#)] [[PubMed](#)]
126. Villarreal, G.; Chatterjee, A.; Oh, S.S.; Oh, D.-J.; Kang, M.H.; Rhee, D.J. Canonical Wnt Signaling Regulates Extracellular Matrix Expression in the Trabecular Meshwork. *Investig. Ophthalmol. Vis. Sci.* **2014**, *55*, 7433–7440. [[CrossRef](#)]
127. Webber, H.C.; Bermudez, J.Y.; Sethi, A.; Clark, A.F.; Mao, W. Crosstalk between TGF β and Wnt Signaling Pathways in the Human Trabecular Meshwork. *Exp. Eye Res.* **2016**, *148*, 97–102. [[CrossRef](#)]
128. Webber, H.C.; Bermudez, J.Y.; Millar, J.C.; Mao, W.; Clark, A.F. The Role of Wnt/ β -Catenin Signaling and K-Cadherin in the Regulation of Intraocular Pressure. *Investig. Ophthalmol. Vis. Sci.* **2018**, *59*, 1454–1466. [[CrossRef](#)]
129. Barthel, A.; Schmoll, D.; Unterman, T.G. FoxO Proteins in Insulin Action and Metabolism. *Trends Endocrinol. Metab. TEM* **2005**, *16*, 183–189. [[CrossRef](#)]
130. Almeida, M.; Ambrogini, E.; Han, L.; Manolagas, S.C.; Jilka, R.L. Increased Lipid Oxidation Causes Oxidative Stress, Increased Peroxisome Proliferator-Activated Receptor-Gamma Expression, and Diminished pro-Osteogenic Wnt Signaling in the Skeleton. *J. Biol. Chem.* **2009**, *284*, 27438–27448. [[CrossRef](#)] [[PubMed](#)]
131. Essers, M.A.G.; de Vries-Smits, L.M.M.; Barker, N.; Polderman, P.E.; Burgering, B.M.T.; Korswagen, H.C. Functional Interaction between Beta-Catenin and FOXO in Oxidative Stress Signaling. *Science* **2005**, *308*, 1181–1184. [[CrossRef](#)] [[PubMed](#)]
132. Hoogeboom, D.; Essers, M.A.G.; Polderman, P.E.; Voets, E.; Smits, L.M.M.; Burgering, B.M.T. Interaction of FOXO with Beta-Catenin Inhibits Beta-Catenin/T Cell Factor Activity. *J. Biol. Chem.* **2008**, *283*, 9224–9230. [[CrossRef](#)] [[PubMed](#)]

133. Reif, K.; Burgering, B.M.; Cantrell, D.A. Phosphatidylinositol 3-Kinase Links the Interleukin-2 Receptor to Protein Kinase B and P70 S6 Kinase. *J. Biol. Chem.* **1997**, *272*, 14426–14433. [[CrossRef](#)]
134. Brunet, A.; Bonni, A.; Zigmond, M.J.; Lin, M.Z.; Juo, P.; Hu, L.S.; Anderson, M.J.; Arden, K.C.; Blenis, J.; Greenberg, M.E. Akt Promotes Cell Survival by Phosphorylating and Inhibiting a Forkhead Transcription Factor. *Cell* **1999**, *96*, 857–868. [[CrossRef](#)]
135. Stahl, M.; Dijkers, P.F.; Kops, G.J.P.L.; Lens, S.M.A.; Coffey, P.J.; Burgering, B.M.T.; Medema, R.H. The Forkhead Transcription Factor FoxO Regulates Transcription of P27Kip1 and Bim in Response to IL-2. *J. Immunol. Baltim. Md 1950* **2002**, *168*, 5024–5031. [[CrossRef](#)]
136. Schmidt, M.; Fernandez de Mattos, S.; van der Horst, A.; Klompmaaker, R.; Kops, G.J.P.L.; Lam, E.W.-F.; Burgering, B.M.T.; Medema, R.H. Cell Cycle Inhibition by FoxO Forkhead Transcription Factors Involves Downregulation of Cyclin D. *Mol. Cell. Biol.* **2002**, *22*, 7842–7852. [[CrossRef](#)]
137. Fernández de Mattos, S.; Essafi, A.; Soeiro, I.; Pietersen, A.M.; Birkenkamp, K.U.; Edwards, C.S.; Martino, A.; Nelson, B.H.; Francis, J.M.; Jones, M.C.; et al. FoxO3a and BCR-ABL Regulate Cyclin D2 Transcription through a STAT5/BCL6-Dependent Mechanism. *Mol. Cell. Biol.* **2004**, *24*, 10058–10071. [[CrossRef](#)]
138. Manolopoulos, K.N.; Klotz, L.-O.; Korsten, P.; Bornstein, S.R.; Barthel, A. Linking Alzheimer’s Disease to Insulin Resistance: The FoxO Response to Oxidative Stress. *Mol. Psychiatry* **2010**, *15*, 1046–1052. [[CrossRef](#)]
139. Shang, Y.C.; Chong, Z.Z.; Hou, J.; Maiese, K. Wnt1, FoxO3a, and NF-KappaB Oversee Microglial Integrity and Activation during Oxidant Stress. *Cell. Signal.* **2010**, *22*, 1317–1329. [[CrossRef](#)]
140. Halleskog, C.; Mulder, J.; Dahlström, J.; Mackie, K.; Hortobágyi, T.; Tanila, H.; Kumar Puli, L.; Färber, K.; Harkany, T.; Schulte, G. WNT Signaling in Activated Microglia Is Proinflammatory. *Glia* **2011**, *59*, 119–131. [[CrossRef](#)]
141. L’episcopo, F.; Serapide, M.F.; Tirollo, C.; Testa, N.; Caniglia, S.; Morale, M.C.; Pluchino, S.; Marchetti, B. A Wnt1 Regulated Frizzled-1/ β -Catenin Signaling Pathway as a Candidate Regulatory Circuit Controlling Mesencephalic Dopaminergic Neuron-Astrocyte Crosstalk: Therapeutical Relevance for Neuron Survival and Neuroprotection. *Mol. Neurodegener.* **2011**, *6*, 49. [[CrossRef](#)]
142. Ma, B.; Hottiger, M.O. Crosstalk between Wnt/ β -Catenin and NF-KB Signaling Pathway during Inflammation. *Front. Immunol.* **2016**, *7*, 378. [[CrossRef](#)]
143. Mitchell, S.; Vargas, J.; Hoffmann, A. Signaling via the NF κ B System. *Wiley Interdiscip. Rev. Syst. Biol. Med.* **2016**, *8*, 227–241. [[CrossRef](#)]
144. Deng, J.; Miller, S.A.; Wang, H.-Y.; Xia, W.; Wen, Y.; Zhou, B.P.; Li, Y.; Lin, S.-Y.; Hung, M.-C. Beta-Catenin Interacts with and Inhibits NF-Kappa B in Human Colon and Breast Cancer. *Cancer Cell* **2002**, *2*, 323–334. [[CrossRef](#)]
145. Liu, J.; Liao, Y.; Ma, K.; Wang, Y.; Zhang, G.; Yang, R.; Deng, J. PI3K Is Required for the Physical Interaction and Functional Inhibition of NF-KB by β -Catenin in Colorectal Cancer Cells. *Biochem. Biophys. Res. Commun.* **2013**, *434*, 760–766. [[CrossRef](#)]
146. Martin, M.; Rehani, K.; Jope, R.S.; Michalek, S.M. Toll-like Receptor-Mediated Cytokine Production Is Differentially Regulated by Glycogen Synthase Kinase 3. *Nat. Immunol.* **2005**, *6*, 777–784. [[CrossRef](#)]
147. Manicassamy, S.; Reizis, B.; Ravindran, R.; Nakaya, H.; Salazar-Gonzalez, R.M.; Wang, Y.-C.; Pulendran, B. Activation of Beta-Catenin in Dendritic Cells Regulates Immunity versus Tolerance in the Intestine. *Science* **2010**, *329*, 849–853. [[CrossRef](#)]
148. Cho, H.H.; Song, J.S.; Yu, J.M.; Yu, S.S.; Choi, S.J.; Kim, D.H.; Jung, J.S. Differential Effect of NF-KappaB Activity on Beta-Catenin/Tcf Pathway in Various Cancer Cells. *FEBS Lett.* **2008**, *582*, 616–622. [[CrossRef](#)] [[PubMed](#)]
149. Fliniaux, I.; Mikkola, M.L.; Lefebvre, S.; Thesleff, I. Identification of Dkk4 as a Target of Eda-A1/Edar Pathway Reveals an Unexpected Role of Ectodysplasin as Inhibitor of Wnt Signalling in Ectodermal Placodes. *Dev. Biol.* **2008**, *320*, 60–71. [[CrossRef](#)] [[PubMed](#)]
150. Hoeflich, K.P.; Luo, J.; Rubie, E.A.; Tsao, M.S.; Jin, O.; Woodgett, J.R. Requirement for Glycogen Synthase Kinase-3beta in Cell Survival and NF-KappaB Activation. *Nature* **2000**, *406*, 86–90. [[CrossRef](#)] [[PubMed](#)]
151. Beurel, E.; Michalek, S.M.; Jope, R.S. Innate and Adaptive Immune Responses Regulated by Glycogen Synthase Kinase-3 (GSK3). *Trends Immunol.* **2010**, *31*, 24–31. [[CrossRef](#)]
152. Lutgen, V.; Narasipura, S.D.; Sharma, A.; Min, S.; Al-Harathi, L. β -Catenin Signaling Positively Regulates Glutamate Uptake and Metabolism in Astrocytes. *J. Neuroinflamm* **2016**, *13*, 242. [[CrossRef](#)] [[PubMed](#)]
153. Narasipura, S.D.; Henderson, L.J.; Fu, S.W.; Chen, L.; Kashanchi, F.; Al-Harathi, L. Role of β -Catenin and TCF/LEF Family Members in Transcriptional Activity of HIV in Astrocytes. *J. Virol.* **2012**, *86*, 1911–1921. [[CrossRef](#)] [[PubMed](#)]
154. Lecarpentier, Y.; Schussler, O.; Hébert, J.-L.; Vallée, A. Molecular Mechanisms Underlying the Circadian Rhythm of Blood Pressure in Normotensive Subjects. *Curr. Hypertens. Rep.* **2020**, *22*, 50. [[CrossRef](#)] [[PubMed](#)]
155. Russo, E.; Guy, G.W. A Tale of Two Cannabinoids: The Therapeutic Rationale for Combining Tetrahydrocannabinol and Cannabidiol. *Med. Hypotheses* **2006**, *66*, 234–246. [[CrossRef](#)]
156. Pertwee, R.G. Endocannabinoids and Their Pharmacological Actions. *Handb. Exp. Pharmacol.* **2015**, *231*, 1–37. [[CrossRef](#)]
157. Bergamaschi, M.M.; Queiroz, R.H.C.; Zuardi, A.W.; Crippa, J.A.S. Safety and Side Effects of Cannabidiol, a Cannabis Sativa Constituent. *Curr. Drug Saf.* **2011**, *6*, 237–249. [[CrossRef](#)]
158. Iffland, K.; Grotenhermen, F. An Update on Safety and Side Effects of Cannabidiol: A Review of Clinical Data and Relevant Animal Studies. *Cannabis Cannabinoid Res.* **2017**, *2*, 139–154. [[CrossRef](#)]
159. Fernández-Ruiz, J.; Sagredo, O.; Pazos, M.R.; García, C.; Pertwee, R.; Mechoulam, R.; Martínez-Orgado, J. Cannabidiol for Neurodegenerative Disorders: Important New Clinical Applications for This Phytocannabinoid? *Br. J. Clin. Pharmacol.* **2013**, *75*, 323–333. [[CrossRef](#)]

160. Devinsky, O.; Cilio, M.R.; Cross, H.; Fernandez-Ruiz, J.; French, J.; Hill, C.; Katz, R.; Di Marzo, V.; Jutras-Aswad, D.; Notcutt, W.G.; et al. Cannabidiol: Pharmacology and Potential Therapeutic Role in Epilepsy and Other Neuropsychiatric Disorders. *Epilepsia* **2014**, *55*, 791–802. [[CrossRef](#)]
161. Emamian, E.S. AKT/GSK3 Signaling Pathway and Schizophrenia. *Front. Mol. Neurosci.* **2012**, *5*, 33. [[CrossRef](#)] [[PubMed](#)]
162. Renard, J.; Norris, C.; Rushlow, W.; Laviolette, S.R. Neuronal and Molecular Effects of Cannabidiol on the Mesolimbic Dopamine System: Implications for Novel Schizophrenia Treatments. *Neurosci. Biobehav. Rev.* **2017**, *75*, 157–165. [[CrossRef](#)]
163. Vallée, A.; Lecarpentier, Y.; Guillevin, R.; Vallée, J.-N. Effects of Cannabidiol Interactions with Wnt/ β -Catenin Pathway and PPAR γ on Oxidative Stress and Neuroinflammation in Alzheimer's Disease. *Acta Biochim. Biophys. Sin.* **2017**, *49*, 853–866. [[CrossRef](#)] [[PubMed](#)]
164. Zhan, G.-L.; Camras, C.B.; Palmberg, P.F.; Toris, C.B. Effects of Marijuana on Aqueous Humor Dynamics in a Glaucoma Patient. *J. Glaucoma* **2005**, *14*, 175–177. [[CrossRef](#)] [[PubMed](#)]
165. Novack, G.D. Cannabinoids for Treatment of Glaucoma. *Curr. Opin. Ophthalmol.* **2016**, *27*, 146–150. [[CrossRef](#)] [[PubMed](#)]
166. Lograno, M.D.; Romano, M.R. Cannabinoid Agonists Induce Contractile Responses through Gi/o-Dependent Activation of Phospholipase C in the Bovine Ciliary Muscle. *Eur. J. Pharmacol.* **2004**, *494*, 55–62. [[CrossRef](#)] [[PubMed](#)]
167. Krishnan, G.; Chatterjee, N. Anandamide Rescues Retinal Barrier Properties in Müller Glia through Nitric Oxide Regulation. *Neuroscience* **2015**, *284*, 536–545. [[CrossRef](#)] [[PubMed](#)]
168. Wang, M.; Zheng, Y. Oxidative Stress and Antioxidants in the Trabecular Meshwork. *PeerJ* **2019**, *7*. [[CrossRef](#)] [[PubMed](#)]
169. Miller, S.; Daily, L.; Leishman, E.; Bradshaw, H.; Straiker, A. Δ^9 -Tetrahydrocannabinol and Cannabidiol Differentially Regulate Intraocular Pressure. *Investig. Ophthalmol. Vis. Sci.* **2018**, *59*, 5904–5911. [[CrossRef](#)]
170. Console-Bram, L.; Brailoiu, E.; Brailoiu, G.C.; Sharir, H.; Abood, M.E. Activation of GPR18 by Cannabinoid Compounds: A Tale of Biased Agonism. *Br. J. Pharmacol.* **2014**, *171*, 3908–3917. [[CrossRef](#)]
171. Leweke, F.M.; Piomelli, D.; Pahlisch, F.; Muhl, D.; Gerth, C.W.; Hoyer, C.; Klosterkötter, J.; Hellmich, M.; Koethe, D. Cannabidiol Enhances Anandamide Signaling and Alleviates Psychotic Symptoms of Schizophrenia. *Transl. Psychiatry* **2012**, *2*, e94. [[CrossRef](#)]
172. Miller, S.; Leishman, E.; Oehler, O.; Daily, L.; Murataeva, N.; Wager-Miller, J.; Bradshaw, H.; Straiker, A. Evidence for a GPR18 Role in Diurnal Regulation of Intraocular Pressure. *Investig. Ophthalmol. Vis. Sci.* **2016**, *57*, 6419–6426. [[CrossRef](#)]
173. Straiker, A. What Is Currently Known about Cannabidiol and Ocular Pressure. *Expert Rev. Ophthalmol.* **2019**, *14*, 259–261. [[CrossRef](#)]
174. Miller, S.; Hu, S.S.-J.; Leishman, E.; Morgan, D.; Wager-Miller, J.; Mackie, K.; Bradshaw, H.B.; Straiker, A. A GPR119 Signaling System in the Murine Eye Regulates Intraocular Pressure in a Sex-Dependent Manner. *Investig. Ophthalmol. Vis. Sci.* **2017**, *58*, 2930–2938. [[CrossRef](#)] [[PubMed](#)]
175. Tomida, I.; Azuara-Blanco, A.; House, H.; Flint, M.; Pertwee, R.G.; Robson, P.J. Effect of Sublingual Application of Cannabinoids on Intraocular Pressure: A Pilot Study. *J. Glaucoma* **2006**, *15*, 349–353. [[CrossRef](#)]
176. Libro, R.; Bramanti, P.; Mazzon, E. The Role of the Wnt Canonical Signaling in Neurodegenerative Diseases. *Life Sci.* **2016**, *158*, 78–88. [[CrossRef](#)] [[PubMed](#)]
177. Libro, R.; Diomedea, F.; Scionti, D.; Piattelli, A.; Grassi, G.; Pollastro, F.; Bramanti, P.; Mazzon, E.; Trubiani, O. Cannabidiol Modulates the Expression of Alzheimer's Disease-Related Genes in Mesenchymal Stem Cells. *Int. J. Mol. Sci.* **2016**, *18*, 26. [[CrossRef](#)] [[PubMed](#)]
178. Giacoppo, S.; Pollastro, F.; Grassi, G.; Bramanti, P.; Mazzon, E. Target Regulation of PI3K/Akt/MTOR Pathway by Cannabidiol in Treatment of Experimental Multiple Sclerosis. *Fitoterapia* **2017**, *116*, 77–84. [[CrossRef](#)]
179. Hernández, F.; Gómez de Barreda, E.; Fuster-Matanzo, A.; Lucas, J.J.; Avila, J. GSK3: A Possible Link between Beta Amyloid Peptide and Tau Protein. *Exp. Neurol.* **2010**, *223*, 322–325. [[CrossRef](#)]
180. Ozaïta, A.; Puighermanal, E.; Maldonado, R. Regulation of PI3K/Akt/GSK-3 Pathway by Cannabinoids in the Brain. *J. Neurochem.* **2007**, *102*, 1105–1114. [[CrossRef](#)]
181. Trazzi, S.; Steger, M.; Mitrugno, V.M.; Bartesaghi, R.; Ciani, E. CB1 Cannabinoid Receptors Increase Neuronal Precursor Proliferation through AKT/Glycogen Synthase Kinase-3 β /Beta-Catenin Signaling. *J. Biol. Chem.* **2010**, *285*, 10098–10109. [[CrossRef](#)]
182. Atalay, S.; Jarocka-Karpowicz, I.; Skrzydlewska, E. Antioxidative and Anti-Inflammatory Properties of Cannabidiol. *Antioxid. Basel Switz.* **2019**, *9*, 21. [[CrossRef](#)] [[PubMed](#)]
183. Borges, R.S.; Batista, J.; Viana, R.B.; Baetas, A.C.; Orestes, E.; Andrade, M.A.; Honório, K.M.; da Silva, A.B.F. Understanding the Molecular Aspects of Tetrahydrocannabinol and Cannabidiol as Antioxidants. *Mol. Basel Switz.* **2013**, *18*, 12663–12674. [[CrossRef](#)]
184. Rajesh, M.; Mukhopadhyay, P.; Bátkai, S.; Haskó, G.; Liaudet, L.; Drel, V.R.; Obrosova, I.G.; Pacher, P. Cannabidiol Attenuates High Glucose-Induced Endothelial Cell Inflammatory Response and Barrier Disruption. *Am. J. Physiol. Heart Circ. Physiol.* **2007**, *293*, H610–H619. [[CrossRef](#)]
185. Pan, H.; Mukhopadhyay, P.; Rajesh, M.; Patel, V.; Mukhopadhyay, B.; Gao, B.; Haskó, G.; Pacher, P. Cannabidiol Attenuates Cisplatin-Induced Nephrotoxicity by Decreasing Oxidative/Nitrosative Stress, Inflammation, and Cell Death. *J. Pharmacol. Exp. Ther.* **2009**, *328*, 708–714. [[CrossRef](#)]
186. Fouad, A.A.; Albuali, W.H.; Al-Mulhim, A.S.; Jresat, I. Cardioprotective Effect of Cannabidiol in Rats Exposed to Doxorubicin Toxicity. *Environ. Toxicol. Pharmacol.* **2013**, *36*, 347–357. [[CrossRef](#)] [[PubMed](#)]

187. Hamelink, C.; Hampson, A.; Wink, D.A.; Eiden, L.E.; Eskay, R.L. Comparison of Cannabidiol, Antioxidants, and Diuretics in Reversing Binge Ethanol-Induced Neurotoxicity. *J. Pharmacol. Exp. Ther.* **2005**, *314*, 780–788. [[CrossRef](#)]
188. Campos, A.C.; Fogaça, M.V.; Sonego, A.B.; Guimarães, F.S. Cannabidiol, Neuroprotection and Neuropsychiatric Disorders. *Pharmacol. Res.* **2016**, *112*, 119–127. [[CrossRef](#)]
189. da Silva, V.K.; de Freitas, B.S.; Garcia, R.C.L.; Monteiro, R.T.; Hallak, J.E.; Zuardi, A.W.; Crippa, J.A.S.; Schröder, N. Antiapoptotic Effects of Cannabidiol in an Experimental Model of Cognitive Decline Induced by Brain Iron Overload. *Transl. Psychiatry* **2018**, *8*, 176. [[CrossRef](#)] [[PubMed](#)]
190. Vomund, S.; Schäfer, A.; Parnham, M.J.; Brüne, B.; von Knethen, A. Nrf2, the Master Regulator of Anti-Oxidative Responses. *Int. J. Mol. Sci.* **2017**, *18*, 2772. [[CrossRef](#)]
191. Rajesh, M.; Mukhopadhyay, P.; Bátkai, S.; Patel, V.; Saito, K.; Matsumoto, S.; Kashiwaya, Y.; Horváth, B.; Mukhopadhyay, B.; Becker, L.; et al. Cannabidiol Attenuates Cardiac Dysfunction, Oxidative Stress, Fibrosis, and Inflammatory and Cell Death Signaling Pathways in Diabetic Cardiomyopathy. *J. Am. Coll. Cardiol.* **2010**, *56*, 2115–2125. [[CrossRef](#)]
192. Costa, B.; Trovato, A.E.; Comelli, F.; Giagnoni, G.; Colleoni, M. The Non-Psychoactive Cannabis Constituent Cannabidiol Is an Orally Effective Therapeutic Agent in Rat Chronic Inflammatory and Neuropathic Pain. *Eur. J. Pharmacol.* **2007**, *556*, 75–83. [[CrossRef](#)] [[PubMed](#)]
193. Wu, H.-Y.; Jan, T.-R. Cannabidiol Hydroxyquinone-Induced Apoptosis of Splenocytes Is Mediated Predominantly by Thiol Depletion. *Toxicol. Lett.* **2010**, *195*, 68–74. [[CrossRef](#)] [[PubMed](#)]
194. Gegotek, A.; Ambrożewicz, E.; Jastrzab, A.; Jarocka-Karpowicz, I.; Skrzydlewska, E. Rutin and Ascorbic Acid Cooperation in Antioxidant and Antiapoptotic Effect on Human Skin Keratinocytes and Fibroblasts Exposed to UVA and UVB Radiation. *Arch. Dermatol. Res.* **2019**, *311*, 203–219. [[CrossRef](#)]
195. Pertwee, R.G. The Pharmacology of Cannabinoid Receptors and Their Ligands: An Overview. *Int. J. Obes.* **2005**, *30* (Suppl. 1), S13–S18. [[CrossRef](#)]
196. Wang, S.; Xu, Q.; Shu, G.; Wang, L.; Gao, P.; Xi, Q.; Zhang, Y.; Jiang, Q.; Zhu, X. N-Oleoyl Glycine, a Lipoamino Acid, Stimulates Adipogenesis Associated with Activation of CB1 Receptor and Akt Signaling Pathway in 3T3-L1 Adipocyte. *Biochem. Biophys. Res. Commun.* **2015**, *466*, 438–443. [[CrossRef](#)] [[PubMed](#)]
197. Wang, Y.; Mukhopadhyay, P.; Cao, Z.; Wang, H.; Feng, D.; Haskó, G.; Mechoulam, R.; Gao, B.; Pacher, P. Cannabidiol Attenuates Alcohol-Induced Liver Steatosis, Metabolic Dysregulation, Inflammation and Neutrophil-Mediated Injury. *Sci. Rep.* **2017**, *7*, 12064. [[CrossRef](#)]
198. Hou, Y.; Moreau, F.; Chadee, K. PPAR γ Is an E3 Ligase That Induces the Degradation of NF κ B/P65. *Nat. Commun.* **2012**, *3*, 1300. [[CrossRef](#)]
199. Lee, C.-H.; Olson, P.; Evans, R.M. Minireview: Lipid Metabolism, Metabolic Diseases, and Peroxisome Proliferator-Activated Receptors. *Endocrinology* **2003**, *144*, 2201–2207. [[CrossRef](#)] [[PubMed](#)]
200. Marx, N.; Duez, H.; Fruchart, J.-C.; Staels, B. Peroxisome Proliferator-Activated Receptors and Atherogenesis: Regulators of Gene Expression in Vascular Cells. *Circ. Res.* **2004**, *94*, 1168–1178. [[CrossRef](#)]
201. Cunard, R.; Ricote, M.; DiCampi, D.; Archer, D.C.; Kahn, D.A.; Glass, C.K.; Kelly, C.J. Regulation of Cytokine Expression by Ligands of Peroxisome Proliferator Activated Receptors. *J. Immunol. Baltim. Md 1950* **2002**, *168*, 2795–2802. [[CrossRef](#)]
202. Ricote, M.; Li, A.C.; Willson, T.M.; Kelly, C.J.; Glass, C.K. The Peroxisome Proliferator-Activated Receptor-Gamma Is a Negative Regulator of Macrophage Activation. *Nature* **1998**, *391*, 79–82. [[CrossRef](#)]
203. Giannini, S.; Serio, M.; Galli, A. Pleiotropic Effects of Thiazolidinediones: Taking a Look beyond Antidiabetic Activity. *J. Endocrinol. Investig.* **2004**, *27*, 982–991. [[CrossRef](#)]
204. Vallée, A.; Lecarpentier, Y. Crosstalk Between Peroxisome Proliferator-Activated Receptor Gamma and the Canonical WNT/ β -Catenin Pathway in Chronic Inflammation and Oxidative Stress During Carcinogenesis. *Front. Immunol.* **2018**, *9*, 745. [[CrossRef](#)] [[PubMed](#)]
205. Vallée, A.; Lecarpentier, Y.; Guillevin, R.; Vallée, J.-N. Thermodynamics in Gliomas: Interactions between the Canonical WNT/ β -Catenin Pathway and PPAR Gamma. *Front. Physiol.* **2017**, *8*, 352. [[CrossRef](#)] [[PubMed](#)]
206. Vallée, A.; Lecarpentier, Y.; Guillevin, R.; Vallée, J.-N. Demyelination in Multiple Sclerosis: Reprogramming Energy Metabolism and Potential PPAR γ Agonist Treatment Approaches. *Int. J. Mol. Sci.* **2018**, *19*, 1212. [[CrossRef](#)]
207. Park, K.S.; Lee, R.D.; Kang, S.-K.; Han, S.Y.; Park, K.L.; Yang, K.H.; Song, Y.S.; Park, H.J.; Lee, Y.M.; Yun, Y.P.; et al. Neuronal Differentiation of Embryonic Midbrain Cells by Upregulation of Peroxisome Proliferator-Activated Receptor-Gamma via the JNK-Dependent Pathway. *Exp. Cell Res.* **2004**, *297*, 424–433. [[CrossRef](#)] [[PubMed](#)]
208. Vallée, A.; Lecarpentier, Y.; Vallée, J.-N. Thermodynamic Aspects and Reprogramming Cellular Energy Metabolism during the Fibrosis Process. *Int. J. Mol. Sci.* **2017**, *18*, 2537. [[CrossRef](#)]
209. Vallée, A.; Lecarpentier, Y.; Guillevin, R.; Vallée, J.-N. Reprogramming Energetic Metabolism in Alzheimer's Disease. *Life Sci.* **2018**, *193*, 141–152. [[CrossRef](#)]
210. Grimes, C.A.; Jope, R.S. The Multifaceted Roles of Glycogen Synthase Kinase 3 β in Cellular Signaling. *Prog. Neurobiol.* **2001**, *65*, 391–426. [[CrossRef](#)]
211. Jeon, M.; Rahman, N.; Kim, Y.-S. Wnt/ β -Catenin Signaling Plays a Distinct Role in Methyl Gallate-Mediated Inhibition of Adipogenesis. *Biochem. Biophys. Res. Commun.* **2016**, *479*, 22–27. [[CrossRef](#)]

212. Gustafson, B.; Eliasson, B.; Smith, U. Thiazolidinediones Increase the Wingless-Type MMTV Integration Site Family (WNT) Inhibitor Dickkopf-1 in Adipocytes: A Link with Osteogenesis. *Diabetologia* **2010**, *53*, 536–540. [[CrossRef](#)] [[PubMed](#)]
213. Osborne, A.L.; Solowij, N.; Babic, I.; Lum, J.S.; Newell, K.A.; Huang, X.-F.; Weston-Green, K. Effect of Cannabidiol on Endocannabinoid, Glutamatergic and GABAergic Signalling Markers in Male Offspring of a Maternal Immune Activation (Poly I:C) Model Relevant to Schizophrenia. *Prog. Neuropsychopharmacol. Biol. Psychiatry* **2019**, *95*, 109666. [[CrossRef](#)] [[PubMed](#)]
214. Piomelli, D. The Molecular Logic of Endocannabinoid Signalling. *Nat. Rev. Neurosci.* **2003**, *4*, 873–884. [[CrossRef](#)] [[PubMed](#)]
215. Campos, A.C.; Fogaça, M.V.; Scarante, F.F.; Joca, S.R.L.; Sales, A.J.; Gomes, F.V.; Sonogo, A.B.; Rodrigues, N.S.; Galve-Roperh, I.; Guimarães, F.S. Plastic and Neuroprotective Mechanisms Involved in the Therapeutic Effects of Cannabidiol in Psychiatric Disorders. *Front. Pharmacol.* **2017**, *8*, 269. [[CrossRef](#)]
216. Viveros, M.P.; Llorente, R.; Suarez, J.; Llorente-Berzal, A.; López-Gallardo, M.; de Fonseca, F.R. The Endocannabinoid System in Critical Neurodevelopmental Periods: Sex Differences and Neuropsychiatric Implications. *J. Psychopharmacol. Oxf. Engl.* **2012**, *26*, 164–176. [[CrossRef](#)]
217. McPartland, J.M.; Duncan, M.; Di Marzo, V.; Pertwee, R.G. Are Cannabidiol and $\Delta(9)$ -Tetrahydrocannabivarin Negative Modulators of the Endocannabinoid System? A Systematic Review. *Br. J. Pharmacol.* **2015**, *172*, 737–753. [[CrossRef](#)] [[PubMed](#)]